var title_f11_35_11824="Pectoralis minor stretch";
var content_f11_35_11824=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Pectoralis minor stretch",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 209px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Stand with your elbow straight and your body at about a 45 degree angle from the wall. Raise your hand between waist and chest height and place your palm flush to the wall. Next, rotate your body away from the wall until you feel a stretch in the front of your biceps area. Hold for 30 seconds. Release the pressure for 5 to 10 seconds. Perform 3 repetitions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig Parsons, MS, PT and the Physical Therapy Network.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11824=[""].join("\n");
var outline_f11_35_11824=null;
var title_f11_35_11825="Tuberculoma of the eye";
var content_f11_35_11825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculoma of the eye",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 271px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Raised yellowish choriodal lesion with surrounding serous elevation of the neurosensory retina, intraretinal exudation and macular star. Retinal vessels are seen over the lesion and appear normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cangemi, FE, Friedman, R, Josephberg, R. Opthalmology 1980; 87:252.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11825=[""].join("\n");
var outline_f11_35_11825=null;
var title_f11_35_11826="Patient information: Age-related vision loss (The Basics)";
var content_f11_35_11826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15850\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28465\">",
"         Common eye disorders",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/11/24754\">",
"         Patient information: Age-related macular degeneration (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6114\">",
"         Patient information: Cataracts (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/34/11810\">",
"         Patient information: Diabetic retinopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2258\">",
"         Patient information: Glaucoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/6/28769\">",
"         Patient information: Presbyopia and refractive errors (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Age-related vision loss (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/age-related-vision-loss-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28696431\">",
"      <span class=\"h1\">",
"       What causes age-related vision loss?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many things that lead to vision loss as you get older. The most common are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cataracts &mdash; A cataract is a clouding of the lens of the eye (",
"        <a class=\"graphic graphic_figure graphicRef76735 \" href=\"UTD.htm?27/51/28465\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Glaucoma &mdash; Glaucoma is a disease that damages the main nerve in the eye, called the optic nerve.",
"       </li>",
"       <li>",
"        Macular degeneration &mdash; Macular degeneration is a condition that damages the back of the eye, called the retina.",
"       </li>",
"       <li>",
"        Diabetic retinopathy &mdash; Diabetic retinopathy damages the retina, too. But in this case the damage is related to having blood sugar levels that are too high. This type of vision loss affects people with diabetes.",
"       </li>",
"       <li>",
"        Presbyopia &mdash; Presbyopia occurs when the lens of the eye can no longer focus the right way. Presbyopia often occurs as a result of aging.",
"       </li>",
"       <li>",
"        Refractive errors &mdash; Refractive errors, such as nearsightedness and farsightedness, happen when the cornea (a structure in the front of the eye) cannot focus light or images onto the back of the eye the right way. Refractive errors can occur at any age, but are common among older people.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28696438\">",
"      <span class=\"h1\">",
"       Who should be tested for age-related vision loss?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Experts recommend that people have at least 1 full eye exam (called a &ldquo;comprehensive eye exam&rdquo;) after they turn 40.",
"     </p>",
"     <p>",
"      If you are 40 or older, you should be tested even if your vision is fine. That&rsquo;s because many eye conditions do not affect vision until they are very advanced. By then, it might be too late to protect your vision. But if you catch a problem early, you can sometimes prevent vision loss.",
"     </p>",
"     <p>",
"      During the comprehensive eye exam, an eye doctor:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Looks into the back of your eye with a magnifying tool to check for signs of nerve damage.",
"       </li>",
"       <li>",
"        Checks how well you see things in the center of focus, and how well you see things that are off to the side.",
"       </li>",
"       <li>",
"        Checks the pressure inside your eye by pushing or blowing on your eye with a special tool. People with glaucoma often have too much pressure inside the eye.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28696445\">",
"      <span class=\"h1\">",
"       What treatments are available?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It depends on the cause of vision loss. For instance, people with cataracts can have surgery to replace the lens in their eye. People with glaucoma can take drops to lower the pressure inside their eyes. With some forms of vision loss, early treatment is very important, because it can prevent further vision loss. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28696452\">",
"      <span class=\"h1\">",
"       Can age-related vision loss be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can reduce your chances of developing vision loss by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Not smoking (or quitting if you already smoke)",
"       </li>",
"       <li>",
"        Keeping your blood sugar and blood pressure levels as close to normal as possible if you have diabetes or high blood pressure",
"       </li>",
"       <li>",
"        Wearing goggles or other types of eye protection when you use heavy machinery or do anything that could hurt your eyes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There is also some evidence that eating a diet rich in fruits and vegetables and low in fat and cholesterol can help prevent vision loss. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28696459\">",
"      <span class=\"h1\">",
"       What if I already have age-related vision loss?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you already have vision loss, remember that there are tools that can help you make the most of the vision you have left. For instance, there are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Magnifying devices that mount on the TV and other screens",
"       </li>",
"       <li>",
"        Large print books",
"       </li>",
"       <li>",
"        Computer programs that allow your computer to read aloud to you",
"       </li>",
"       <li>",
"        Braille books &mdash; Braille is a form of language that uses raised dots. People who are blind read braille by passing their fingers over these dots.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28696541\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=see_link\">",
"       Patient information: Cataracts (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=see_link\">",
"       Patient information: Glaucoma (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=see_link\">",
"       Patient information: Age-related macular degeneration (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=see_link\">",
"       Patient information: Diabetic retinopathy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/6/28769?source=see_link\">",
"       Patient information: Presbyopia and refractive errors (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/35/11826?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15850 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-2CA427E3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11826=[""].join("\n");
var outline_f11_35_11826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28696431\">",
"      What causes age-related vision loss?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28696438\">",
"      Who should be tested for age-related vision loss?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28696445\">",
"      What treatments are available?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28696452\">",
"      Can age-related vision loss be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28696459\">",
"      What if I already have age-related vision loss?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28696541\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28465\">",
"      Common eye disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/11/24754?source=related_link\">",
"      Patient information: Age-related macular degeneration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6114?source=related_link\">",
"      Patient information: Cataracts (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/13/2258?source=related_link\">",
"      Patient information: Glaucoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/6/28769?source=related_link\">",
"      Patient information: Presbyopia and refractive errors (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_35_11827="Patient information: Diet and health (The Basics)";
var content_f11_35_11827=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16157\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39413\">",
"         Nutrition label",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"          Foods and drinks with calcium and vitamin D",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/12/36034\">",
"         Patient information: Calcium and vitamin D for bone health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36483\">",
"         Patient information: Diabetes and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/51/35634\">",
"         Patient information: High-fiber diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/59/7091\">",
"         Patient information: Starting solid foods with babies (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/15/6387\">",
"         Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/38/40546\">",
"         Patient information: Vitamin supplements (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/52/31554\">",
"         Patient information: Weight loss treatments (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/60/23491\">",
"         Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/62/28642\">",
"         Patient information: Diet and health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/39/8817\">",
"         Patient information: High-fiber diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/32/41476\">",
"         Patient information: Starting solid foods during infancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/32/31239\">",
"         Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33876\">",
"         Patient information: Weight loss treatments (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Diet and health (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/diet-and-health-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H26962714\">",
"      <span class=\"h1\">",
"       Why is it important to eat a healthy diet?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to eat a healthy diet because eating the right foods can keep you healthy now and later on in life.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26962721\">",
"      <span class=\"h1\">",
"       Which foods are especially healthy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Foods that are especially healthy include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fruits and vegetables &mdash; Eating fruits and vegetables can help prevent heart disease and strokes. Eating them might also help prevent certain types of cancers. Try to eat fruits and vegetables at each meal and for snacks. If you don&rsquo;t have fresh fruits and vegetables, you can eat frozen or canned ones instead. Doctors recommend eating 5 or more servings of fruits and vegetables each day.",
"       </li>",
"       <li>",
"        Foods with fiber &mdash; Eating foods with a lot of fiber can help prevent heart disease and strokes. If you have type 2 diabetes, it can also help control your blood sugar. Foods that have a lot of fiber include vegetables, fruits, beans, nuts, oatmeal, and some breads and cereals. You can tell how much fiber is in a food by reading the nutrition label (",
"        <a class=\"graphic graphic_figure graphicRef51585 \" href=\"UTD.htm?38/31/39413\">",
"         figure 1",
"        </a>",
"        ). Doctors recommend eating 20 to 35 grams of fiber each day.",
"       </li>",
"       <li>",
"        Foods with folate (also called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"         folic acid",
"        </a>",
"        ) &mdash; Folate is a vitamin that is important for pregnant women and women who plan to get pregnant. Pregnant women need to get enough folate so that their unborn baby can grow normally. Folate is found in many breakfast cereals, oranges, orange juice, and green leafy vegetables.",
"       </li>",
"       <li>",
"        Foods with calcium and vitamin D &mdash; Babies, children, and adults need calcium and vitamin D to help keep their bones strong. Adults also need calcium and vitamin D to help prevent osteoporosis. Osteoporosis is a condition that causes bones to get thin and break more easily than usual. Different foods and drinks have calcium and vitamin D in them (",
"        <a class=\"graphic graphic_figure graphicRef79375 \" href=\"UTD.htm?18/13/18647\">",
"         figure 2",
"        </a>",
"        ). People who don&rsquo;t get enough calcium and vitamin D in their diet might need to take a supplement. Supplements are pills, capsules, liquids, or tablets that have nutrients in them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26962728\">",
"      <span class=\"h1\">",
"       What about fats?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are different types of fats. Some types of fats are better for your body than others. Unhealthy fats are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trans fats &mdash; These are found in margarines, many fast foods, and some store-bought baked goods.",
"       </li>",
"       <li>",
"        Saturated fats &mdash; These are found in red meats, butter, and many cheeses.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Both trans fats and saturated fats can raise your cholesterol level and your chance of getting heart disease. Try to avoid eating foods with these types of fats.",
"     </p>",
"     <p>",
"      Healthier fats are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Monounsaturated fats",
"       </li>",
"       <li>",
"        Polyunsaturated fats",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When you cook, use oils with these healthier fats, such as olive oil and canola oil.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26962735\">",
"      <span class=\"h1\">",
"       What about alcohol?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People who drink a small amount of alcohol each day might have a lower chance of getting heart disease. But drinking alcohol can lead to problems. For example, it can raise a person&rsquo;s chances of getting liver disease and certain types of cancers.",
"     </p>",
"     <p>",
"      Most doctors recommend that adult women not have more than 1 drink a day and that adult men not have more than 2 drinks a day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26962742\">",
"      <span class=\"h1\">",
"       How many calories do I need each day?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The number of calories you need each day depends on your weight, height, age, sex, and how active you are.",
"     </p>",
"     <p>",
"      Your doctor or nurse can tell you how many calories you should eat each day. If you are trying to lose weight, you should eat fewer calories each day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26962749\">",
"      <span class=\"h1\">",
"       What if I have questions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have questions about which foods you should or should not eat, ask your doctor or nurse. The right diet for you will depend, in part, on your health and any medical conditions you have.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H26962756\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=see_link\">",
"       Patient information: Diabetes and diet (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=see_link\">",
"       Patient information: Weight loss treatments (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/59/7091?source=see_link\">",
"       Patient information: Starting solid foods with babies (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=see_link\">",
"       Patient information: High-fiber diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=see_link\">",
"       Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=see_link\">",
"       Patient information: Vitamin supplements (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       Patient information: Diet and health (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"       Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=see_link\">",
"       Patient information: High-fiber diet (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"       Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=see_link\">",
"       Patient information: Weight loss treatments (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=see_link\">",
"       Patient information: Starting solid foods during infancy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/35/11827?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16157 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-190.92.87.115-3AD7EB5AF7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11827=[""].join("\n");
var outline_f11_35_11827=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26962714\">",
"      Why is it important to eat a healthy diet?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26962721\">",
"      Which foods are especially healthy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26962728\">",
"      What about fats?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26962735\">",
"      What about alcohol?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26962742\">",
"      How many calories do I need each day?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26962749\">",
"      What if I have questions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26962756\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16157\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39413\">",
"      Nutrition label",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/13/18647\">",
"       Foods and drinks with calcium and vitamin D",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/40/36483?source=related_link\">",
"      Patient information: Diabetes and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/39/8817?source=related_link\">",
"      Patient information: High-fiber diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/51/35634?source=related_link\">",
"      Patient information: High-fiber diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/32/41476?source=related_link\">",
"      Patient information: Starting solid foods during infancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/59/7091?source=related_link\">",
"      Patient information: Starting solid foods with babies (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=related_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/15/6387?source=related_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/38/40546?source=related_link\">",
"      Patient information: Vitamin supplements (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33876?source=related_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/52/31554?source=related_link\">",
"      Patient information: Weight loss treatments (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_35_11828="High cytokeratin stain";
var content_f11_35_11828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic adulthood ductopenia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a portal triad from a liver biopsy using a CK7 cytokeratin immunostain specific for biliary epithelium from an adult with idiopathic ductopenia. The portal tract lacks a bile duct but is surrounded by brown staining, representing focal ductular proliferation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Hart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11828=[""].join("\n");
var outline_f11_35_11828=null;
var title_f11_35_11829="Membranous VSD with aneurysm color still frame";
var content_f11_35_11829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Membranous VSD with aneurysm color still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paired long axis images with and without color flow mapping demonstrating tricuspid valve tissue apposed to the ventricular septal defect (VSD, arrows) which is partially occluding the defect. In the right hand panel, color flow mapping demonstrates residual flow around this tricuspid valve tissue.",
"    <div class=\"footnotes\">",
"     LV: left ventricle; LA: left atrium; RV: right ventricle; AO: aorta; MV: mitral valve; arrows: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11829=[""].join("\n");
var outline_f11_35_11829=null;
var title_f11_35_11830="Nerves of the male perineum";
var content_f11_35_11830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51485&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Nerves of the male perineum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11830=[""].join("\n");
var outline_f11_35_11830=null;
var title_f11_35_11831="Valproate: Patient drug information";
var content_f11_35_11831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Valproate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     see \"Valproate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     see \"Valproate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Depacon&reg;;",
"     </li>",
"     <li>",
"      Depakene&reg;;",
"     </li>",
"     <li>",
"      Depakote&reg;;",
"     </li>",
"     <li>",
"      Depakote&reg; ER;",
"     </li>",
"     <li>",
"      Depakote&reg; Sprinkle;",
"     </li>",
"     <li>",
"      Stavzor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Divalproex&reg;;",
"     </li>",
"     <li>",
"      Apo-Valproic&reg;;",
"     </li>",
"     <li>",
"      Depakene&reg;;",
"     </li>",
"     <li>",
"      Dom-Divalproex;",
"     </li>",
"     <li>",
"      Epival&reg;;",
"     </li>",
"     <li>",
"      Mylan-Divalproex;",
"     </li>",
"     <li>",
"      Mylan-Valproic;",
"     </li>",
"     <li>",
"      Novo-Divalproex;",
"     </li>",
"     <li>",
"      Nu-Divalproex;",
"     </li>",
"     <li>",
"      PHL-Divalproex;",
"     </li>",
"     <li>",
"      PHL-Valproic Acid;",
"     </li>",
"     <li>",
"      PHL-Valproic Acid E.C.;",
"     </li>",
"     <li>",
"      PMS-Divalproex;",
"     </li>",
"     <li>",
"      PMS-Valproic Acid;",
"     </li>",
"     <li>",
"      PMS-Valproic Acid E.C.;",
"     </li>",
"     <li>",
"      ratio-Valproic;",
"     </li>",
"     <li>",
"      ratio-Valproic ECC;",
"     </li>",
"     <li>",
"      Rhoxal-valproic;",
"     </li>",
"     <li>",
"      Sandoz-Valproic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13213314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232263",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad and sometimes deadly liver problems. Children under 2 years old may be at greater risk. Call your doctor if you see dark urine, are feeling tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad and sometimes deadly pancreas problems (pancreatitis). This could happen in children or adults at any time during care. Signs of pancreatitis include belly pain, upset stomach, throwing up, or not feeling hungry. Call your doctor right away if you have any of these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4232496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause harm to the unborn baby if you take it while you are pregnant. If you get pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13213316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bipolar problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692146",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given to you for other reasons. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13213315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to valproic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2749554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to peanuts, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4236002",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Liver disease or a urea cycle disorder.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194403",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This is not a list of all drugs or health problems that interact with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13213320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4201327",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To lower the chance of feeling dizzy or passing out, rise slowly over a few minutes when sitting or lying down. Be careful climbing stairs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4193826",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you drink beer, wine, mixed drinks, or use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697181",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you stop taking this drug all of a sudden, you may have signs of withdrawal. Tell your doctor if you have any bad effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may affect certain lab tests. Be sure your doctor and lab workers know you take this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 65 or older, use this drug with care. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697758",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use caution in children. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13213321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4192396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling sleepy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling more or less hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation or swelling where the shot was given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13213323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4186197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hearing loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4236126",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Memory problems or loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699103",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unable to pass urine or change in the amount of urine passed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swollen gland.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4186199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble controlling body movements, twitching, change in balance, trouble swallowing or speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4236125",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Patients who take this drug may be at a greater risk of having thoughts or actions of suicide. The risk may be greater in people who have had these thoughts or actions in the past. Watch people who take this drug closely. Call the doctor right away if signs like low mood (depression), nervousness, restlessness, grouchiness, panic attacks, or changes in mood or actions are new or worse. Call the doctor right away if any thoughts or actions of suicide occur.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to Health Canada's Canada Vigilance Program at 1-866-234-2345.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13213318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4236128",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All Oral Products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. This could cause seizures. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablets and capsules:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4236143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you see parts of the tablet in your stool, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of Depakote&reg; Sprinkle&reg; capsule on soft food or liquid. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4236142",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may see Depakote&reg; Sprinkle&reg; bits in the stool.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Measure liquid doses carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13213319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13213324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13213325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11136 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11831=[""].join("\n");
var outline_f11_35_11831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233020\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233021\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213314\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213316\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213315\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213320\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213321\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213323\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213318\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213319\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213324\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13213325\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=related_link\">",
"      Valproate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=related_link\">",
"      Valproate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_35_11832="The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum";
var content_f11_35_11832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The role of angiogenesis inhibitors in epithelial carcinoma of the ovary, fallopian tube, or peritoneum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/35/11832/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11832/contributors\">",
"     Michael J Birrer, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11832/contributors\">",
"     Bradley J Monk, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/35/11832/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11832/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/35/11832/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11832/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/35/11832/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H459224741\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics and behavior. As such, these are often combined and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice. This topic will consider all three histologies under the heading EOC. EOC is the most common cause of death among women with gynecologic malignancies and the fifth leading cause of cancer death in women in the United States. Treatment generally requires aggressive surgical evaluation and the use of adjuvant chemotherapy. For those with recurrence, chemotherapy is the mainstay of treatment, with surgery reserved for select situations.",
"   </p>",
"   <p>",
"    The development of a blood supply is a necessary prerequisite for tumor growth. A dominant factor controlling tumor angiogenesis is vascular endothelial growth factor (VEGF). Angiogenesis plays a fundamental role in normal ovarian physiology and in the pathogenesis of EOC, progression through ascites formation, and metastatic spread [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. VEGF and VEGF receptor (VEGFR) are expressed in EOC, and increased VEGF expression has been associated with the development of malignant ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. This data provides the rationale for targeting VEGF and VEGFR in the treatment of EOC.",
"   </p>",
"   <p>",
"    This topic will review the role of angiogenesis inhibitors in EOC. The treatment of EOC and a general overview of angiogenesis inhibitors are covered separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link\">",
"       Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"       Overview of angiogenesis inhibitors",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11858079\">",
"    <span class=\"h1\">",
"     BEVACIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is a humanized monoclonal antibody that binds VEGF and prevents it from binding to its receptor. This blocks growth and maintenance of tumor-associated blood vessels. It has been studied in different treatment settings in EOC as described below. While promising results in EOC have been reported, no studies have demonstrated an improvement in quality of life or overall survival with incorporation of bevacizumab into a treatment program. A general discussion on bevacizumab is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"     \"Overview of angiogenesis inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459225053\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant therapy is an integral component of treatment for the majority of women with newly diagnosed EOC. Despite the intention to give chemotherapy with curative intent, the vast majority of women with EOC will relapse. Studies have evaluated the benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to adjuvant treatment as a way to improve outcomes. While bevacizumab can prolong progression-free survival, it has not shown an effect on quality of life or overall survival. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14635776\">",
"    <span class=\"h2\">",
"     Recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of relapsed EOC is stratified based upon the amount of time that has elapsed between the completion of platinum-based treatment and the detection of relapse, known as the platinum-free interval (PFI):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a PFI of six months or longer are considered to have &ldquo;platinum sensitive&rdquo; disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with a PFI of less than six months are considered to have &ldquo;platinum-resistant&rdquo; disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    evaluated its use in patients with relapsed EOC, regardless of platinum sensitivity. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Gynecologic Group Trial 170D (GOG 170D), 62 women with relapsed EOC received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every three weeks) until disease progression or unacceptable toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/5\">",
"       5",
"      </a>",
"      ]. Of those enrolled, 66 percent had received two prior regimens and 42 percent were considered platinum-resistant. The overall response rate (ORR) was 21 percent and progression-free survival (PFS) at six months was 40 percent. Serious adverse events (grade 4) included one episode each of pulmonary embolus, vomiting and constipation, and proteinuria. None of these patients experienced a gastrointestinal (GI) perforation.",
"     </li>",
"     <li>",
"      In a trial of 70 women with recurrent EOC who had received up to two prior regimens, treatment consisted of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two weeks) and oral metronomic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      on a 28-day cycle [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/6\">",
"       6",
"      </a>",
"      ]. The ORR was 24 percent and PFS at six months was 56 percent. Four women experienced a serious GI event (perforation or fistula formation). Three treatment-related deaths were reported. In a third phase II trial, 13 patients with recurrent EOC who had received up to two prior regimens received bevacizumab (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 21 days) with an oral epidermal growth factor inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      (150 mg daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/7\">",
"       7",
"      </a>",
"      ]. The ORR was 15 percent and PFS at six months was 38 percent. Two patients experienced a fatal GI perforation. The study was terminated early due to the suggestion that this combination was not better than single agent bevacizumab.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequently, several studies have been performed specifically in both platinum-sensitive and platinum-resistant EOC. A discussion of its use in these specific situations is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link&amp;anchor=H1846264342#H1846264342\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\", section on 'Is there a role for bevacizumab?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link&amp;anchor=H1142138325#H1142138325\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\", section on 'Biologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H282374298\">",
"    <span class=\"h2\">",
"     The role of CA-125 in monitoring response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor marker CA-125 may not be an accurate predictor of treatment response to anti-angiogenesis agents. In one retrospective analysis of 15 women treated with the biologic combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    for recurrent EOC, five of seven patients who responded by imaging also had a response by CA-125 criteria; three women who experienced a durable response (lasting &gt;20, &gt;22, and &gt;24 months) would have had treatment terminated earlier if only CA-125 was used [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/8\">",
"     8",
"    </a>",
"    ]. This may be an important issue in response assessment for women receiving therapy with this drug. The use of CA-125 in the management of patients with EOC is presented in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=see_link&amp;anchor=H1105882#H1105882\">",
"     \"Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum\", section on 'Role of CA-125 surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7846656\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with EOC who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    have similar risks as those who receive bevacizumab for other cancer indications. These include new or worsening hypertension, proteinuria, thrombotic events, bleeding, altered wound healing, and gastrointestinal perforation (GIP). Given that women with EOC often present or recur with peritoneal involvement, the risk of GIP has been of significant concern and is discussed below. A more detailed review of toxicity is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459225092\">",
"    <span class=\"h3\">",
"     Risk of gastrointestinal perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    should be considered at risk for gastrointestinal perforation (GIP), and early detection might help reduce the morbidity and mortality of this complication. For patients with new-onset abdominal pain, the diagnosis of GIP should be evaluated urgently with a complete history, physical examination (to rule out signs of peritonitis), and abdominal imaging (ie, radiograph to evaluate for free air or non-contrast computed tomography). Details regarding the risk of GIP associated with bevacizumab and the diagnosis of GIP are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link&amp;anchor=H20#H20\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Diffuse abdominal pain syndromes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1651227451#H1651227451\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Intestinal perforation/fistula formation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459225108\">",
"    <span class=\"h1\">",
"     NOVEL AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials are evaluating other antiangiogenic agents for women with EOC. Other angiogenesis pathways involved in EOC pathogenesis include platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF). Higher PDGF levels have been observed in ovarian carcinomas than in benign tissue and in malignant ascites, and have been linked to poor survival [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Additional evidence supports the involvement of the FGF pathway in angiogenesis, ovarian physiology, and ascites formation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/10,13-15\">",
"     10,13-15",
"    </a>",
"    ]. Moreover, both PDGF and FGF signaling pathways appear to be involved in VEGF resistance described across various solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/10,13,16,17\">",
"     10,13,16,17",
"    </a>",
"    ]. This suggests that combined inhibition of VEGF and PDGF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    FGF may more completely block angiogenesis than VEGF inhibition alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/13,18-20\">",
"     13,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cardiovascular and non-cardiovascular toxicity of agents that target angiogenesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459225116\">",
"    <span class=\"h2\">",
"     Aflibercept (VEGF-Trap)",
"    </span>",
"    &nbsp;&mdash;&nbsp;VEGF-Trap is a fusion protein that binds to both VEGF receptors, VEGFR1 and VEGFR2 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/21\">",
"     21",
"    </a>",
"    ]. Initial studies suggested activity of single agent VEGF-Trap in women with heavily pretreated EOC [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/22\">",
"     22",
"    </a>",
"    ]. In a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    trial, 46 women (33 with platinum-resistant EOC) were treated with VEGF-Trap (6",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    every 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/23\">",
"     23",
"    </a>",
"    ]. The overall response rate was 54 percent with a median duration of response of six months. Median progression-free and overall survival was 6 and 27 months, respectively. Serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included neutropenia, fatigue, dyspnea, and stomatitis. Further studies of this agent are underway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459225124\">",
"    <span class=\"h2\">",
"     AMG-386",
"    </span>",
"    &nbsp;&mdash;&nbsp;AMG386 is an angiopoietin antagonist petide-Fc fusion protein (also known as a peptibody) that inhibits angiopoietin-1 and angiopoietin-2 from binding their tyrosine kinase receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/24\">",
"     24",
"    </a>",
"    ]. In a randomized phase II trial, 161 women with recurrent epithelial EOC were given weekly paclitaxel in combination with placebo or AMG386 at a low-dose (3",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or high-dose (10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/25\">",
"     25",
"    </a>",
"    ]. Treatment was administered weekly for three weeks on a four-week cycle. The median progression free survival times were 5, 6, and 7 months, respectively. The overall response rates were 27, 19, and 37 percent, respectively. CA-125 responses were recorded in 28, 58, and 71 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H459225132\">",
"    <span class=\"h2\">",
"     BIBF 1120",
"    </span>",
"    &nbsp;&mdash;&nbsp;BIBF 1120 is an oral angiokinase inhibitor that targets VEGFR-1, -2, and -3,",
"    <span class=\"nowrap\">",
"     PDGFR-alfa/beta,",
"    </span>",
"    FGFR-1, -2, and -3, members of the sarcoma viral oncogene homolog (Src) family, and fms-like tyrosine kinase 3 (Flt-3) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/26\">",
"     26",
"    </a>",
"    ]. The following studies have evaluated this agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of 84 women with recurrent epithelial EOC who had responded to their last (second-line or higher) chemotherapy randomly assigned treatment with either BIBF 1120 (250 mg twice daily) or placebo as maintenance therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/27\">",
"       27",
"      </a>",
"      ]. Compared to placebo, BIBF1120 was associated with a higher proportion of patients without progression at six months (16 versus 5 percent). The incidence of serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      adverse events was similar with BIBF 1120 and placebo (35 versus 28 percent). Hepatic enzyme elevations were significantly more common with BIBF 1120 compared to placebo (52 versus 8 percent, respectively).",
"     </li>",
"     <li>",
"      A phase I study evaluated the use of standard chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ) plus BIBF 1120 (100 to 250 mg) in 22 women with recurrent gynecologic malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/28\">",
"       28",
"      </a>",
"      ]. All patients experienced gastrointestinal adverse events (AEs), which were mostly mild (grade",
"      <span class=\"nowrap\">",
"       1/2).",
"      </span>",
"      In patients treated BIBF1120 200 or 250 mg twice daily, diarrhea and alanine aminotransferase (ALT) elevations were the most common serious events followed by leukopenia, neutropenia, and aspartate aminotransferase (AST) elevation. Five of seven evaluable patients responded to combination therapy (across all dose levels). All ten patients evaluated with CA-125 experienced a serologic response. Patients who did not progress during the combination phase were eligible to receive BIBF 1120 maintenance monotherapy; among 16 patients who received BIBF 1120 monotherapy, one dose-limiting toxicity was reported (ALT elevation).",
"     </li>",
"     <li>",
"      A phase III trial is investigating the combination of",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT01015118\">",
"       BIBF 1120 with carboplatin and paclitaxel",
"      </a>",
"      in the first-line setting followed by BIBF 1120 maintenance therapy until disease progression or for a maximum of 120 weeks after randomization in this population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14636576\">",
"    <span class=\"h2\">",
"     Sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     Sorafenib",
"    </a>",
"    targets VEGFR-2 and -3, PDGFR-beta, stem cell factor receptor (c-kit), Flt-3, and v-raf 1 murine leukemia viral oncogene homolog 1 (Raf) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/29\">",
"     29",
"    </a>",
"    ]. Studies of sorafenib in EOC have had mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Gynecologic Oncology Group Trial 170 F (GOG 170F), 71 patients with recurrent EOC and who had received up to three prior lines of therapy were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (400 mg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/30\">",
"       30",
"      </a>",
"      ]. The six-month progression-free survival rate was 24 percent (90% CI, 15 to 35 percent), with median progression-free and overall survival of 2 and 16 months, respectively. The most common serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities were metabolic, hand-foot syndrome, and rash. There were no reports of gastrointestinal perforation. &nbsp;",
"     </li>",
"     <li>",
"      A phase II trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      400 mg twice daily plus weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      in pretreated EOC failed to meet its primary endpoint (overall response rate &ge; 35 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A German phase II trial found that adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      400 mg twice daily to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      as neoadjuvant therapy for patients with advanced stage",
"      <span class=\"nowrap\">",
"       IIIC/IV",
"      </span>",
"      EOC was not feasible; serious toxicity necessitated the withdrawal of the first four enrolled patients and early closure of the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase II study is evaluating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      versus placebo as maintenance therapy in patients with stage",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      EOC who have achieved clinical complete remission (confirmed by standard computed tomography or magnetic resonance imaging) after surgical debulking and standard adjuvant platinum plus taxane chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14636584\">",
"    <span class=\"h2\">",
"     Pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    targets VEGFR-1, -2, and -3,",
"    <span class=\"nowrap\">",
"     PDGFR-alfa/beta,",
"    </span>",
"    FGFR-1 and -3, and c-kit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/33\">",
"     33",
"    </a>",
"    ]. A phase II open-label study evaluated pazopanib 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in 36 patients with pretreated recurrent EOC (no prior antiangiogenic therapy) with complete CA-125 response to initial platinum-based chemotherapy and subsequent CA-125 elevation to &ge;42",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/34\">",
"     34",
"    </a>",
"    ]. A CA-125 response was seen in 31 percent which persisted for a median of 113 days. An additional 56 percent met criteria for stable disease which lasted a median of 80 days. In patients with measurable disease at baseline, the overall response rate was 18 percent. The most common severe (grade 3) adverse events were fatigue and &gamma;-glutamyl transpeptidase elevation (11 percent for each) followed by diarrhea and ALT elevation (8 percent for each). One patient developed grade 4 peripheral edema.",
"   </p>",
"   <p>",
"    A",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00866697\">",
"     phase III trial is evaluating pazopanib versus placebo",
"    </a>",
"    for 52 weeks as maintenance therapy in patients with non-bulky stage II-IV EOC, with a response or stable disease after surgical debulking and at least five cycles of first-line chemotherapy (AGO-OVAR16).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14636592\">",
"    <span class=\"h2\">",
"     Cediranib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cediranib targets VEGFR-1, -2, and -3,",
"    <span class=\"nowrap\">",
"     PDGFR-alfa/beta,",
"    </span>",
"    FGFR-1, and c-kit [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/35\">",
"     35",
"    </a>",
"    ]. Cediranib has been evaluated in two phase II studies in patients with either platinum-resistant or platinum-sensitive recurrent EOC showing promising activity.",
"   </p>",
"   <p>",
"    In one study, 46 patients were treated with cediranib at a dose of 45 mg orally once a day [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/36\">",
"     36",
"    </a>",
"    ]. However the dose was reduced to 30 mg daily due to toxicity in the first 11 patients. The overall response rate was 17 percent. Thirty percent of patients demonstrated a response or had clinically or molecularly (CA-125) stable disease lasting greater than 16 weeks. Serious (grade 3) toxicities included hypertension (46 percent), fatigue (24 percent), and diarrhea (13 percent). Median progression free survival was 5 months and overall survival had not been reached with median follow-up of 11 months.",
"   </p>",
"   <p>",
"    In a two-stage phase II trial, 60 women with EOC who had received only one prior line of treatment were treated with cediranib (45 mg initially then 30 mg daily due to toxicity) until progression or toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11832/abstract/37\">",
"     37",
"    </a>",
"    ]. Serious (grade 3) toxicity included hypertension (33 percent) and fatigue (20 percent). Seventy percent of patients demonstrated a response or had clinically or molecularly (CA125) stable disease lasting greater than 16 weeks (49 percent in women with platinum-sensitive disease and 29 percent in those with platinum-resistant disease). The median time to progression was 4 months and overall survival was 12 months. &nbsp;",
"   </p>",
"   <p>",
"    A multi-stage phase III trial is assessing the safety and efficacy of platinum-based chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) alone versus chemotherapy with concurrent cediranib versus chemotherapy with concurrent and maintenance cediranib in platinum-sensitive relapsed EOC (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/show/NCT00532194\">",
"     ICON 6",
"    </a>",
"    ) is in progress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link&amp;anchor=H1224704057#H1224704057\">",
"     \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\", section on 'Single agent therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15667734\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epithelial cancers of ovarian, fallopian tubal, and peritoneal origin exhibit similar clinical characteristics and behavior. As such, these are often combined and define epithelial ovarian cancer (EOC) in clinical trials and clinical practice.",
"     </li>",
"     <li>",
"      For women with newly diagnosed with EOC, treatment requires aggressive surgical evaluation and the use of adjuvant chemotherapy. For those with recurrence, chemotherapy is the mainstay of treatment, with surgery reserved for select situations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Angiogenesis plays a fundamental role in normal ovarian physiology as well as in the pathogenesis of EOC, promoting tumor growth and progression through ascites formation and metastatic spread. Vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) are expressed in EOC, and increased VEGF expression has been associated with the development of malignant ascites. (See",
"      <a class=\"local\" href=\"#H459224741\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      to adjuvant chemotherapy for women with newly diagnosed EOC can improve progression-free survival, but it has not shown an effect on overall survival. (See",
"      <a class=\"local\" href=\"#H459225053\">",
"       'Adjuvant therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=see_link&amp;anchor=H284998595#H284998595\">",
"       \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\", section on 'Incorporation of angiogenesis inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      has activity in recurrent EOC in combination with chemotherapy or as a single agent and is a reasonable treatment option for women with recurrent platinum-resistant EOC. (See",
"      <a class=\"local\" href=\"#H14635776\">",
"       'Recurrent disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=see_link&amp;anchor=H1142138325#H1142138325\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease\", section on 'Biologic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CA-125 may not be an accurate predictor of treatment response to anti-angiogenesis agents and should be used cautiously in defining response for women on treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H282374298\">",
"       'The role of CA-125 in monitoring response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      should be considered at risk for gastrointestinal perforation (GIP). Acute mortality is high following the diagnosis of GIP and early detection might help reduce the morbidity and mortality of this complication. Patients with confirmed or highly suspected GIP whose overall condition is unstable secondary to the GIP should be considered for immediate surgical repair or diversion. Those who are more stable can be considered for less invasive management strategies such as bowel rest and broad-spectrum antibiotics with or without percutaneous drainage of concurrent abscesses. Acute patient condition, quality of life, and overall prognosis should be important factors in the decision to explore these patients surgically. (See",
"      <a class=\"local\" href=\"#H459225092\">",
"       'Risk of gastrointestinal perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Novel anti-angiogenesis agents are being explored in clinical trials. All women should be encouraged to participate in well designed, prospective clinical trials. (See",
"      <a class=\"local\" href=\"#H459225108\">",
"       'Novel agents'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/1\">",
"      Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/2\">",
"      Ramakrishnan S, Subramanian IV, Yokoyama Y, Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005; 8:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/3\">",
"      Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 2011; 121:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/4\">",
"      Chen H, Ye D, Xie X, et al. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004; 94:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/5\">",
"      Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/6\">",
"      Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/7\">",
"      Nimeiri HS, Oza AM, Morgan RJ, et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008; 110:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/8\">",
"      Azad NS, Annunziata CM, Steinberg SM, et al. Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy. Cancer 2008; 112:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/9\">",
"      Apte SM, Bucana CD, Killion JJ, et al. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol 2004; 93:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/10\">",
"      Lu C, Thaker PH, Lin YG, et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008; 198:477.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/11\">",
"      Matei D, Emerson RE, Lai YC, et al. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 2006; 25:2060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/12\">",
"      Wilczynski SP, Chen YY, Chen W, et al. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum Pathol 2005; 36:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/13\">",
"      Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/14\">",
"      Steele IA, Edmondson RJ, Bulmer JN, et al. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene 2001; 20:5878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/15\">",
"      Whitworth MK, Backen AC, Clamp AR, et al. Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endothelium. Clin Cancer Res 2005; 11:4282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/16\">",
"      Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/17\">",
"      Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/18\">",
"      Bergers G, Song S, Meyer-Morse N, et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/19\">",
"      Laschke MW, Elitzsch A, Vollmar B, et al. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006; 21:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/20\">",
"      Lu C, Kamat AA, Lin YG, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007; 13:4209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/21\">",
"      Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets 2011; 10:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/22\">",
"      Dizon DS. Where do Antiangiogenic Agents Belong in the Treatment Algorithm for Ovarian Cancer? Am J Clin Oncol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/23\">",
"      Coleman RL, Duska LR, Ramirez PT, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011; 12:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/24\">",
"      Robson EJ, Ghatage P. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Expert Opin Investig Drugs 2011; 20:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/25\">",
"      Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2012; 30:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/26\">",
"      Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68:4774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/27\">",
"      Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011; 29:3798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/28\">",
"      du Bois A, Huober J, Stopfer P, et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol 2010; 21:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/29\">",
"      Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/30\">",
"      Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/31\">",
"      Welch SA, Hirte HW, Elit L, et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 2010; 20:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/32\">",
"      P&ouml;lcher M, Eckhardt M, Coch C, et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 2010; 66:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/33\">",
"      Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007; 6:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/34\">",
"      Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010; 119:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/35\">",
"      Lindsay CR, MacPherson IR, Cassidy J. Current status of cediranib: the rapid development of a novel anti-angiogenic therapy. Future Oncol 2009; 5:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/36\">",
"      Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27:5601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11832/abstract/37\">",
"      Hirte HW, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial (Abstract #5521). J Clin Oncol 2008; 26s:5521.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16559 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-BD889E7001-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11832=[""].join("\n");
var outline_f11_35_11832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15667734\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459224741\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11858079\">",
"      BEVACIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459225053\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14635776\">",
"      Recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H282374298\">",
"      The role of CA-125 in monitoring response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7846656\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H459225092\">",
"      - Risk of gastrointestinal perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H459225108\">",
"      NOVEL AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459225116\">",
"      Aflibercept (VEGF-Trap)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459225124\">",
"      AMG-386",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H459225132\">",
"      BIBF 1120",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14636576\">",
"      Sorafenib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14636584\">",
"      Pazopanib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14636592\">",
"      Cediranib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15667734\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/17/29977?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5624?source=related_link\">",
"      Overview of epithelial carcinoma of the ovary, fallopian tube, and peritoneum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_35_11833="Whipple's disease";
var content_f11_35_11833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Whipple's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/35/11833/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11833/contributors\">",
"     Michael D Apstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11833/contributors\">",
"     Thomas Schneider, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/35/11833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11833/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/35/11833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/35/11833/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/35/11833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH Whipple described a 36-year-old clinician in 1907 with \"gradual loss of weight and strength, stools consisting chiefly of neutral fat and fatty acids, indefinite abdominal signs, and a peculiar multiple arthritis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient died of this progressive illness; Whipple called it intestinal lipodystrophy since he observed accumulation of \"large masses of neutral fats and fatty acids in the lymph spaces.\" It was renamed Whipple's disease in 1949 upon description of the sine qua non of this disorder, accumulation of macrophages in the lamina propria with intensely PAS positive intracellular material [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/2\">",
"     2",
"    </a>",
"    ]. An infectious etiology was suspected as early as Whipple's initial report; however, successful treatment with antibiotics was not reported until 1952 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scientific understanding of the histology, immunology and treatment of Whipple's disease has improved since the initial description, and the etiologic agent was identified in 1991. The cause is now known to be Tropheryma whipplei (from the Greek \"trophe\", nourishment, and \"eryma\", barrier, in reference to the nutrient malabsorption characteristic of the disease), a discovery made upon application of a new technique for identifying microbes based upon the DNA sequence encoding their 16S ribosomal RNA. T. whipplei is closely related to many other soil-borne Actinomycetes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whipple suspected an infectious agent in 1907 when he noted the numerous \"rod-shaped organisms\" within the submucosa and macrophages. Careful light and electron microscopy by numerous investigators between 1960 and 1992 subsequently identified a gram-positive, non-acid-fast, periodic acid-Schiff (PAS) positive bacillus with a characteristic trilamellar plasma membrane surrounded by a cell wall (",
"    <a class=\"graphic graphic_picture graphicRef65007 \" href=\"UTD.htm?39/41/40600\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Application of polymerase chain reaction (PCR) allowed identification of a unique bacterial 16S ribosomal RNA in the intestinal and lymphatic tissue of five patients with Whipple's disease that was absent in 10 control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/5\">",
"     5",
"    </a>",
"    ]. This technique relies upon the use of PCR to amplify DNA, using short DNA sequences (primers) common to DNA encoding all bacterial 16S ribosomal RNA; it can be used to identify Tropheryma whipplei in fresh or formalin-fixed intestinal and lymphatic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/5\">",
"     5",
"    </a>",
"    ], vitreous fluid in Whipple's uveitis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/6\">",
"     6",
"    </a>",
"    ], peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/7\">",
"     7",
"    </a>",
"    ], cardiac valves [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/8\">",
"     8",
"    </a>",
"    ], cerebrospinal fluid (CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/9\">",
"     9",
"    </a>",
"    ], and synovial fluid and tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data indicate that T. whipplei, a gram-positive bacillus related to Actinomycetes, causes Whipple's disease. Culture of the organism had not been achieved until a report in which T. whipplei was propagated in cell culture; deactivation of peripheral blood monocytes with interleukin-4 was required for intracellular growth to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/11\">",
"     11",
"    </a>",
"    ]. Unfortunately, this culture technique could not be reproduced [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a group from France was able to grow the organism in a human fibroblast cell line (HEL), subculture it successfully, demonstrate characteristic morphology by electron microscopy, and raise antibodies in mice that reacted with patient samples by immunofluorescence [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/13\">",
"     13",
"    </a>",
"    ]. The specimen was obtained from the heart valve of a patient with endocarditis caused by Whipple's disease. The organism has also been isolated from duodenal mucosa and CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It appears to grow slowly (with a generation time estimated at four days in the report of successful cultivation from the CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/15\">",
"     15",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    A cell-free culture system for T. whipplei using defined culture medium was developed, based on the genome analysis of metabolic pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/16\">",
"     16",
"    </a>",
"    ]. However, it is unclear if the bacteria grown in cell-free culture medium are biologically and immunologically identical with those grown in cell culture.",
"   </p>",
"   <p>",
"    T. whipplei has been cultured from the feces of a patient with Whipple's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/17\">",
"     17",
"    </a>",
"    ]. The investigators decontaminated the specimen with glutaraldehyde, to which the organism is uniquely resistant, in order to isolate the bacterium and cultivate it in a specific axenic medium. The strain, which has been repeatedly subcultured, was confirmed by genotyping to be the same as that found in the duodenal biopsy specimen from the patient. The authors speculate that the organism may be transmitted by fecal-oral contamination; the fact that it is resistant to glutaraldehyde is problematic as this substance is widely used for disinfection.",
"   </p>",
"   <p>",
"    In vitro susceptibility testing of T. whipplei to antibiotics in cell culture using a real-time PCR assay found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , macrolides, ketolides, aminoglycosides, penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , teicoplanin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , and TMP-SMX had activity, with MICs ranging from 0.25 to 2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. A combination of doxycycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    was bactericidal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/19\">",
"     19",
"    </a>",
"    ]. Cephalosporins, polymyxin, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    are less active against intracellular T. whipplei.",
"   </p>",
"   <p>",
"    Fluoroquinolones are not active against T. whipplei. Sequence analysis of the gyrA and parC genes identified amino acid substitutions associated with increased fluoroquinolone resistance in Escherichia coli; these amino acid substitutions are thus likely responsible for intrinsic fluoroquinolone resistance in T. whipplei [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, T. whipplei does not contain the gene that encodes dihydrofolate reductase, the target for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    activity; thus the activity of TMP-SMX is due to sulfamethoxazole alone [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of infections due to T. whipplei is wide. The bacterium has been described among young children with gastroenteritis; in a study including 241 samples from children aged 2 to 4 years, T. whipplei was found in 15 percent of cases; one-third were coinfected with other diarrhea pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/21\">",
"     21",
"    </a>",
"    ]. T. whipplei DNA has also been detected in stool and saliva specimens from asymptomatic individuals; the prevalence depends on the geographic area [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. In Europe, the prevalence of the bacterium in fecal samples from the healthy adult population is estimated to be 1 to 11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, the bacterium has been detected in sewage and is more prevalent in the fecal samples of sewage workers (12 to 26 percent) than the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    T. whipplei has also been observed to be a cause of fever in rural West Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/31\">",
"     31",
"    </a>",
"    ]. Among 204 patients with fever, T. whipplei bacteremia was observed in 13 cases (6.4 percent). Associated clinical symptoms included cough and sleep disturbances.",
"   </p>",
"   <p>",
"    Late onset Whipple's disease is extremely rare. Between 1907 and 1987 there were 696 reported cases; the annual incidence since 1980 has been approximately 30 cases per year. The disorder has a predilection for white males of European ancestry, suggesting an underlying genetic predisposition that leads to colonization of T. whipplei throughout the intestinal tract, lymphoreticular system, and central nervous system upon exposure to soil microbes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, not all individuals that encounter the agent develop Whipple's disease. The patient demographics of Whipple's disease are illustrated in a review of 664 patients that found [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      86 percent were male, with a mean age at diagnosis of 49 years",
"     </li>",
"     <li>",
"      Only 10 (1.5 percent) were of African descent, three Indian, one American Indian, and one Japanese",
"     </li>",
"     <li>",
"      Thirty-five percent were farmers, and 66 percent had occupational exposure to soil or animals",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been no consistent familial clustering other than rare reports. An association between Whipple's disease and HLA-B27 has been postulated but not confirmed [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. An association between HLA alleles DRB1*13 and DQB1*06 and Whipple's disease has been shown in a cohort of 122 European patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of Whipple's disease remains obscure. However, the sequencing of the genome of the organism [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/36\">",
"     36",
"    </a>",
"    ] is likely to facilitate studies of pathogenesis. Invasion or uptake of the bacillus is widespread throughout the body, including the intestinal epithelium, macrophages, capillary and lymphatic endothelium, colon, liver, brain, heart, lung, synovium, kidney, bone marrow, and skin. All of these sites show a remarkable lack of inflammatory response to the bacillus. In addition, the organism exerts no visible cytotoxic effects upon host cells, thereby allowing massive accumulation of T. whipplei at sites of infection.",
"   </p>",
"   <p>",
"    The clinical manifestations of infection do not seem to be determined by pathogen specific factors; no correlation has been observed between variable genomic sequences of T. whipplei and clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lack of immunologic response has led many investigators to implicate host immune deficiency as a predisposition to the disease. This hypothesis is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with Whipple's disease have consistently shown decreased reactivity to mitogens such as phytohemagglutinin (PHA) and concanavalin-A, but have normal levels of immunoglobulins, suggesting a specific defect in cell-mediated immunity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Populations of intestinal and peripheral T-cells in acute Whipple's disease are characterized by a low",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      T-cell ratio, increased activation, and a shift towards mature T-cell subpopulations [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/38-40\">",
"       38-40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Whipple's disease is associated with a low functional activity of type 1 T-helper cells (Th1) in the periphery and the intestinal mucosa. In contrast, functional Th2 responses, characterized by enhanced expression of interleukin-4 (IL-4), are increased [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment with recombinant interferon gamma (IFN gamma) together with antimicrobials has led to clearance of infection in a chronically relapsing patient [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a similarity between Whipple's disease and intestinal Mycobacterium avium complex (MAC) infection in patients with AIDS.",
"     </li>",
"     <li>",
"      Antigen presentation by the MHC class II apparatus is absent or diminished on the intestinal epithelial cells of patients with active Whipple's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/43\">",
"       43",
"      </a>",
"      ]. These findings normalize with treatment, suggesting a secondary effect such as immune downregulation by the bacteria [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may be a defect in host mononuclear cells, manifested by persistent deficiency in the expression of complement receptor type 3 (CD11b) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/38\">",
"       38",
"      </a>",
"      ], persistently diminished ability to degrade intracellular organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/44\">",
"       44",
"      </a>",
"      ], and impaired production of interleukin-12, an important stimulator of T-cell function [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/38,40\">",
"       38,40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As noted above, deactivation of macrophages by IL-4 is required for growth of T. whipplei in cell culture [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with Whipple's disease have impaired immune function of monocytes and macrophages. In such patients, a reduced number of inducible nitrite synthetase-positive macrophages has been observed. Incubation of peripheral monocytes from Whipple's disease patients results in the expression of CD163, a marker of alternatively activated monocytes. This may explain the reduced oxidative burst upon incubation with T. whipplei observed in Whipple's disease patients but not in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The organism is detectable in the saliva in up to 35 percent of healthy individuals and in the dental plaque and feces of healthy hosts [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/22-25\">",
"       22-25",
"      </a>",
"      ], although it is rarely found in intestinal mucosa in the absence of histopathologic evidence of Whipple's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IgG antibodies against T. whipplei are detectable in about 70 percent of healthy individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/13\">",
"       13",
"      </a>",
"      ], in accordance with the theory of frequent exposure to the potential pathogen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Analysis of the transcriptional profile of intestinal macrophages in a patient with therapy refractory intestinal Whipple's disease, revealed up-regulation of genes encoding CCL18, IL-10, cathepsin, MHC class II, scavenger receptor, CD14, and IL-1. All these up-regulated genes have been associated with the",
"    <span class=\"nowrap\">",
"     M2/alternatively",
"    </span>",
"    activated phenotype of macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with Whipple's disease, T. whipplei replication was higher than in healthy subjects and was related to high levels of circulating IL-16 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/49\">",
"     49",
"    </a>",
"    ]. Both events were corrected in patients who successfully responded to antibiotic treatment.",
"   </p>",
"   <p>",
"    Using T. whipplei lysates for specific stimulation of peripheral blood and mucosal lymphocytes from healthy controls and from patients with Whipple's disease lead to intracellular IFN gamma production only in healthy controls but not in Whipple's disease patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/50\">",
"     50",
"    </a>",
"    ]. The reaction of lymphocytes on stimulation with antigens from other pathogens was equivalent in the two groups. These data indicate a specific immunological defect in Whipple's disease patients.",
"   </p>",
"   <p>",
"    Taken together, these observations suggest underlying host immune deficiency and possibly secondary immune downregulation induced by the bacterium. This results in accumulation of massive numbers of organisms within the intestinal tract, and subsequent impaired nutrient absorption. However, patients with Whipple's disease do not appear to be prone to opportunistic infections or to malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four cardinal clinical manifestations of late onset Whipple's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arthralgias",
"     </li>",
"     <li>",
"      Weight loss",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients typically present with migratory arthralgias of the large joints or, less often, a chronic, migratory nondeforming oligoarthritis or polyarthritis which may precede other symptoms by many years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/52\">",
"     52",
"    </a>",
"    ]. In one report of 52 patients, for example, the frequency of abnormalities before diagnosis was: articular (67 percent); gastrointestinal (15 percent); systemic (14 percent); and central nervous system (CNS, 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ]. In this series, musculoskeletal symptoms were observed in 36 patients (67 percent of cases); of these, 55 percent had arthralgias and 45 percent had arthritis. Articular symptoms preceded the diagnosis of Whipple's disease by a mean of six years.",
"   </p>",
"   <p>",
"    Later in the course, diarrhea and weight loss progress to a severe wasting syndrome, with late findings including abdominal distention due to ascites or massive adenopathy. Dementia and other central nervous system findings (such as supranuclear ophthalmoplegia, nystagmus, and myoclonus) occur more frequently (21 percent in one series) in the later stages of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less common symptoms include fever and skin hyperpigmentation. Hyperpigmentation may occur as a consequence of vitamin D malabsorption, which may induce compensatory secondary hyperparathyroidism leading to enhanced MSH and ACTH production [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, infection with T. whipplei may induce hypothalamic dysfunction and adrenal gland insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/54\">",
"     54",
"    </a>",
"    ]. Malabsorption of vitamin B12 may also contribute to hyperpigmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may also be symptoms or signs related to cardiac disease (dyspnea, pericarditis, culture-negative endocarditis), pleuropulmonary (pleural effusion), or mucocutaneous disease; nonthrombocytopenic purpura and prosthetic joint infections can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51,56-58\">",
"     51,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CNS disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive dysfunction is the most common abnormality among those with CNS disease but two findings, at least one of which is present in approximately 20 percent of such patients, are considered pathognomonic for Whipple's disease: oculomasticatory myorhythmia (continuous rhythmic movements of eye convergence with concurrent contractions of the masticatory muscles), and oculo-facial-skeletal myorhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51,59\">",
"     51,59",
"    </a>",
"    ]. These abnormalities are almost always accompanied by supranuclear vertical gaze palsy.",
"   </p>",
"   <p>",
"    Cerebellar ataxia may be a more common feature of CNS disease than previously reported; in a retrospective review of 11 patients, cerebellar ataxia was present in five [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/60\">",
"     60",
"    </a>",
"    ]. A variety of other neurologic findings have been described in case series, including dementia, myoclonus, hemiparesis, peripheral neuropathy, seizures, and upper motor neuron disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isolated neurologic involvement is rare and is difficult to recognize. A case report with a review of the literature identified 20 patients with primary Whipple's disease of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/62\">",
"     62",
"    </a>",
"    ]. Two clinical syndromes were identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multifarious neurological symptoms and signs (eg, generalized seizures, ataxia, eye movement disorders, amnesic syndrome, syndrome of inappropriate anti-diuretic hormone secretion [SIADH], obstructive sleep apnea, insomnia, meningoencephalitis, hemiplegia, dementia, and others) and multiple enhancing lesions on CT or MRI (13 of 18 evaluable cases, 72 percent)",
"     </li>",
"     <li>",
"      Focal neurologic symptoms secondary to a solitary mass lesion (5 of 18 evaluable cases, 28 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whipple endocarditis has been described in a small number of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/13,51,57,63-65\">",
"     13,51,57,63-65",
"    </a>",
"    ]. However, T. whipplei may be a more frequent cause of endocarditis than previously recognized. In a study of 255 patients whose explanted heart valves were positive for bacterial 16S rRNA gene amplification, T. whipplei was detected in 16 (6.3 percent) and was the most common cause of culture-negative endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endocarditis caused by T. whipplei may not be associated with the classical clinical presentation of Whipple's disease. Affected patients may have no clinical or histologic evidence of gastrointestinal disease or arthralgias [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/63-67\">",
"     63-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases, the diagnosis has been made by examination of the resected valve tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/65\">",
"     65",
"    </a>",
"    ]. The pathologic features include significant fibrosis, slight inflammation with foamy macrophages, lack of calcifications, and vegetations of intermediate size [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/65\">",
"     65",
"    </a>",
"    ]. The prominent fibrosis with only slight inflammation suggests a slowly progressive infection, similar to that seen in Q fever and bartonellosis, which are other causes of culture-negative endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/68\">",
"     68",
"    </a>",
"    ]. T. whipplei can be detected in the resected valve by immunohistochemical analysis, which correlates with detection by culture or polymerase chain reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although Whipple's disease has a reputation as a great mimicker of many different illnesses, the difficulty in diagnosis is probably more a function of its rarity than its stealth. It should be considered in all patients with the four cardinal manifestations noted above. Suspicion of the diagnosis is more difficult in those patients (15 percent in one series) who do not develop gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common clinical syndromes that suggest the possible diagnosis of Whipple's disease include fever of unknown origin, chronic serositis, progressive central nervous system disease with myoclonus or ophthalmoplegia, migratory polyarthropathy, and generalized lymphadenopathy. Vitamin or iron deficiency anemia, hypoalbuminemia, and relative lymphopenia should increase the level of suspicion.",
"   </p>",
"   <p>",
"    Among the disorders which should be excluded prior to making a diagnosis of Whipple's disease are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperthyroidism",
"     </li>",
"     <li>",
"      Connective tissue disease",
"     </li>",
"     <li>",
"      Inflammatory bowel disease with migratory polyarthropathy",
"     </li>",
"     <li>",
"      AIDS",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Endoscopy with small bowel biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper gastrointestinal endoscopy with biopsies of the small intestine is the diagnostic test of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51,59\">",
"     51,59",
"    </a>",
"    ]. A prothrombin time should be checked prior to biopsy because of the frequent occurrence of vitamin K malabsorption.",
"   </p>",
"   <p>",
"    The diagnosis of Whipple's disease is usually readily apparent upon PAS staining of duodenal biopsies and is unlikely to be confused with other diseases. The main findings are extensive PAS-positive material in the lamina propria [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/2,69\">",
"     2,69",
"    </a>",
"    ] and villous atrophy (",
"    <a class=\"graphic graphic_picture graphicRef61070 \" href=\"UTD.htm?33/13/34006\">",
"     picture 2",
"    </a>",
"    ). HIV-associated mycobacterial infections have a similar biopsy appearance. However, Whipple's disease is extremely rare in HIV-infected patients and the offending mycobacterium can be readily identified in stool samples. Nevertheless, confirmatory electron microscopy to demonstrate T. whipplei should be performed if the diagnosis is in doubt (",
"    <a class=\"graphic graphic_picture graphicRef65007 \" href=\"UTD.htm?39/41/40600\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The use of PCR techniques on intestinal biopsies remains limited to specialized research laboratories and is not necessary to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, if PCR testing is performed, the amplified DNA should be sequenced. In one series of 30 specimens from patients with histologically confirmed Whipple's disease, the sensitivity and specificity of PCR were 97 and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/71\">",
"     71",
"    </a>",
"    ]. Lower specificity was found in another study that estimated the test to be 95 percent specific when performed on a duodenal biopsy, and 87 percent specific when performed on gastric juice [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/22\">",
"     22",
"    </a>",
"    ]. False positive tests might result from the presence of T. whipplei or a closely related bacterium, which may be present in a substantial proportion of the population in the absence of Whipple's disease. Additionally, PCR tests are at risk of contamination by environmental DNA, lack visual controls, and are difficult to perform on paraffin sections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis can only be made with demonstration of PAS-positive macrophages on small bowel biopsy. Quantitative PCR of saliva and stool specimens can be performed as a first line noninvasive screening for classical Whipple's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/73\">",
"     73",
"    </a>",
"    ]. When the results for both types of specimens are positive, Whipple's disease should be suspected, especially if a high bacterial load is detected. This technique has been used by French investigators but is not available in the United States.",
"   </p>",
"   <p>",
"    PCR of saliva and stool specimens lacks sensitivity for diagnosis of localized Whipple's disease (non-classical), so invasive samples should also be tested on the basis of clinical manifestations. If small bowel biopsies are nondiagnostic, PCR testing can be applied to CSF, brain, lymph node, resected cardiac valves, or liver [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51,65\">",
"     51,65",
"    </a>",
"    ]. PCR performed on peripheral blood has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since neurologic manifestations of Whipple's disease have the most fatal consequences, CSF should be investigated by PCR in any case where the diagnosis is entertained. In one report, for example, PCR and cytology identified infection in the CSF of four of five patients (80 percent) with Whipple's disease and neurologic symptoms, 7 of 10 patients (70 percent) without neurologic symptoms before therapy, and 3 of 11 patients (27 percent) without neurologic symptoms during or after therapy. In four patients treated with antibiotics, PCR test results went from a positive to a negative result [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Development an immunofluorescence assay using the cultured organism has been pursued, although cross-reactivity might make clinical use of this tool difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Use of western blot serology has been described to distinguish between asymptomatic carriers and patients with clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whipple's disease was uniformly fatal prior to the availability of antibiotics. The first successful use of antibiotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    ) was reported in 1952 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     Tetracycline",
"    </a>",
"    was the mainstay of therapy for many years, before a comprehensive review demonstrated a relapse rate of 35 percent among patients treated primarily with tetracycline [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/77\">",
"     77",
"    </a>",
"    ]. The rate of CNS relapse was also high, and retreatment of CNS relapse with tetracycline was not effective.",
"   </p>",
"   <p>",
"    Subsequent empiric management consisted of parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX, one double-strength tablet twice daily) maintenance therapy for one year. The rationale for prolonged therapy is to permit complete eradication of the organism, thereby reducing the likelihood of relapse.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    appears superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    in inducing clinical remission; this was illustrated in a retrospective study including 30 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/78\">",
"     78",
"    </a>",
"    ]. TMP-SMX induced remission in 12 of 13 treatment cycles (92 percent); tetracycline induced 13 of 22 treatment cycles (59 percent). In addition, TMP-SMX was more effective for CNS disease although it was not curative in all cases.",
"   </p>",
"   <p>",
"    Prospective trials have compared the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    for two weeks followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for one year to prevent central nervous system manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. These studies demonstrated very good response rates in both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several reported cases of Jarisch-Herxheimer reactions one to two hours after initial therapy of Whipple's disease with intravenous antibiotics, especially penicillin. The reaction consists of fever of 39&ordm; to 40&ordm;C, chills, headache, hypotension, and severe abdominal pain or pleuritic chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The response to treatment can be monitored by following the patient's hematocrit, weight, and symptom resolution. Surveillance endoscopy and small bowel biopsy are not necessary and may be misleading since PAS staining material may persist long after clinical resolution of the disease; this probably represents dead organisms rather than a propensity to relapse. It has been suggested, however, that follow-up PCR testing may have greater predictive value. In one series of small bowel biopsies obtained after successful initial therapy, relapse occurred in none of five patients who were PCR-negative compared to 12 of 17 who were PCR-positive [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most adequately treated patients do well. Clinical improvement is often dramatic, occurring within 7 to 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ]. The two major problems are CNS disease and relapsing infection. A case report suggested that the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20308?source=see_link\">",
"     recombinant human interferon gamma",
"    </a>",
"    might be beneficial in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Central nervous system disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;CNS involvement continues to be very difficult to manage. The incidence of CNS disease increases over time in an infected patient [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/39\">",
"     39",
"    </a>",
"    ]. In patients with CNS symptoms, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain may reveal nonspecific focal lesions that generally resolve with therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that PCR of the cerebrospinal fluid is often positive in patients without neurologic symptoms suggests that late CNS symptoms probably reflect progression of initially occult infection [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/75\">",
"     75",
"    </a>",
"    ]. Similarly, CNS relapses are thought to reflect primary infection that was not eradicated during initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ]. Supporting information for these hypotheses comes from a report of the successful cultivation of T. whipplei from the CSF of two patients with intestinal involvement but no neurologic symptoms or signs; one of these patients had completed 12 months of therapy with remission of intestinal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although TMP-SMX has been the treatment of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"     51",
"    </a>",
"    ], it is not curative in all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/78\">",
"     78",
"    </a>",
"    ] and relapse can occur even while the patient is taking the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. This has led to the suggestion that initial therapy for CNS disease should consist of an intravenous agent, which attains high CSF levels and is active against T. whipplei, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV once daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (4 MU IV every 4 hours) for four weeks (",
"    <a class=\"graphic graphic_table graphicRef65520 \" href=\"UTD.htm?36/22/37228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/82\">",
"     82",
"    </a>",
"    ]. This should be followed by one year or more of maintenance therapy with oral TMP-SMX (one double strength tablet twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses have been reported in as many as 17 to 35 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/51,83\">",
"     51,83",
"    </a>",
"    ] and, as noted above, in 12 of 17 patients who remained PCR-positive on small bowel biopsy obtained after initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/71\">",
"     71",
"    </a>",
"    ]. It is assumed that relapses reflect incomplete eradication of the organism with initial therapy.",
"   </p>",
"   <p>",
"    Relapses should be treated with initial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV twice daily for four weeks) followed by one year or more of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) or TMP-SMX (one double strength tablet twice daily) (",
"    <a class=\"graphic graphic_table graphicRef65520 \" href=\"UTD.htm?36/22/37228\">",
"     table 1",
"    </a>",
"    ). If a CNS relapse occurs after a lower dose of ceftriaxone, a higher dose (2 g IV twice daily) may be more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/82\">",
"     82",
"    </a>",
"    ]. Occasional patients have required chronic intravenous ceftriaxone therapy for control of CNS symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immune reconstitution",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first few weeks following initiation of antibiotic treatment, some patients may develop symptoms of relapse or disease progression manifested by high fever [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. Those at risk for developing an immune reconstitution inflammatory syndrome (IRIS) after starting therapy for Whipple's disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have been treated with immunosuppressive therapy for presumed rheumatic disease for an extended period prior to the diagnosis of Whipple's disease, whose immunosuppressive therapy is discontinued at the start of antibiotic treatment.",
"     </li>",
"     <li>",
"      Patients with CNS involvement of Whipple's disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these circumstances, corticosteroid therapy may be beneficial; further study is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment regimens in more severely ill patients consist of an initial phase of intravenously administered antibiotics known to penetrate the blood-brain barrier, followed by 12 months of oral maintenance treatment (",
"    <a class=\"graphic graphic_table graphicRef65520 \" href=\"UTD.htm?36/22/37228\">",
"     table 1",
"    </a>",
"    ). We suggest initial therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV once daily) or penicillin (2 MU IV every 4 hours) for two weeks, followed by TMP-SMX (one double-strength tablet twice a day) for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/86\">",
"     86",
"    </a>",
"    ]. For sulfa allergic patients, an alternative maintenance therapy is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg PO twice daily) in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (200 mg PO thrice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/19\">",
"     19",
"    </a>",
"    ]. For ceftriaxone and penicillin allergic patients, we suggest TMP-SMX (one double-strength tablet three times daily) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    (1 g IM daily) for two to four weeks, followed by TMP-SMX (one double-strength tablet twice a day) for one year.",
"   </p>",
"   <p>",
"    For patients with endocarditis, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (2 MU IV every 4 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV once daily) for four weeks, followed by TMP-SMX (one double-strength tablet twice a day) for one year. Surgical resection of the infected valve is usually also needed.",
"   </p>",
"   <p>",
"    For patients with CNS disease we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV once daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (4 MU IV every 4 hours) for four weeks, followed by TMP-SMX (one double-strength tablet twice a day) for one year.",
"   </p>",
"   <p>",
"    For patients who relapse, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    (4 MU IV every 4 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g IV twice daily) for four weeks",
"    <strong>",
"     followed by",
"    </strong>",
"    oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (200 mg PO thrice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/35/11833/abstract/18\">",
"     18",
"    </a>",
"    ]&nbsp;",
"    <strong>",
"     OR",
"    </strong>",
"    TMP-SMX (one double-strength tablet twice a day) for one year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whipple's disease is due to infection with T. whipplei, a gram-positive bacillus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whipple's disease has a variety of clinical manifestations; late onset disease should be considered in patients who present with migratory arthralgias of the large joints, weight loss, diarrhea, and abdominal pain. CNS manifestations are common and varied. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is established by demonstrating the organism on small bowel biopsy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of Whipple's disease varies with different sites of infection (",
"      <a class=\"graphic graphic_table graphicRef65520 \" href=\"UTD.htm?36/22/37228\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Recommendations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/1\">",
"      Whipple GH. A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Bull Johns Hopkins Hosp 1907; 18:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/2\">",
"      BLACK-SCHAFFER B. The tinctoral demonstration of a glycoprotein in Whipple's disease. Proc Soc Exp Biol Med 1949; 72:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/3\">",
"      PAULLEY JW. A case of Whipple's disease (intestinal lipodystrophy). Gastroenterology 1952; 22:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/4\">",
"      Wilson KH, Blitchington R, Frothingham R, Wilson JA. Phylogeny of the Whipple's-disease-associated bacterium. Lancet 1991; 338:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/5\">",
"      Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 1992; 327:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/6\">",
"      Rickman LS, Freeman WR, Green WR, et al. Brief report: uveitis caused by Tropheryma whippelii (Whipple's bacillus). N Engl J Med 1995; 332:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/7\">",
"      Lowsky R, Archer GL, Fyles G, et al. Brief report: diagnosis of Whipple's disease by molecular analysis of peripheral blood. N Engl J Med 1994; 331:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/8\">",
"      Wendler D, Mendoza E, Schleiffer T, et al. Tropheryma whippelii endocarditis confirmed by polymerase chain reaction. Eur Heart J 1995; 16:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/9\">",
"      Cohen L, Berthet K, Dauga C, et al. Polymerase chain reaction of cerebrospinal fluid to diagnose Whipple's disease. Lancet 1996; 347:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/10\">",
"      O'Duffy JD, Griffing WL, Li CY, et al. Whipple's arthritis: direct detection of Tropheryma whippelii in synovial fluid and tissue. Arthritis Rheum 1999; 42:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/11\">",
"      Schoedon G, Goldenberger D, Forrer R, et al. Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii. J Infect Dis 1997; 176:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/12\">",
"      Swartz MN. Whipple's disease--past, present, and future. N Engl J Med 2000; 342:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/13\">",
"      Raoult D, Birg ML, La Scola B, et al. Cultivation of the bacillus of Whipple's disease. N Engl J Med 2000; 342:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/14\">",
"      Raoult D, La Scola B, Lecocq P, et al. Culture and immunological detection of Tropheryma whippelii from the duodenum of a patient with Whipple disease. JAMA 2001; 285:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/15\">",
"      Maiwald M, von Herbay A, Fredricks DN, et al. Cultivation of Tropheryma whipplei from cerebrospinal fluid. J Infect Dis 2003; 188:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/16\">",
"      Renesto P, Crapoulet N, Ogata H, et al. Genome-based design of a cell-free culture medium for Tropheryma whipplei. Lancet 2003; 362:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/17\">",
"      Raoult D, Fenollar F, Birg ML. Culture of T. whipplei from the stool of a patient with Whipple's disease. N Engl J Med 2006; 355:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/18\">",
"      Masselot F, Boulos A, Maurin M, et al. Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm. Antimicrob Agents Chemother 2003; 47:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/19\">",
"      Boulos A, Rolain JM, Raoult D. Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells. Antimicrob Agents Chemother 2004; 48:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/20\">",
"      Boulos A, Rolain JM, Mallet MN, Raoult D. Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium. J Antimicrob Chemother 2005; 55:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/21\">",
"      Raoult D, Fenollar F, Rolain JM, et al. Tropheryma whipplei in children with gastroenteritis. Emerg Infect Dis 2010; 16:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/22\">",
"      Ehrbar HU, Bauerfeind P, Dutly F, et al. PCR-positive tests for Tropheryma whippelii in patients without Whipple's disease. Lancet 1999; 353:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/23\">",
"      Street S, Donoghue HD, Neild GH. Tropheryma whippelii DNA in saliva of healthy people. Lancet 1999; 354:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/24\">",
"      Zinkernagel AS, Gm&uuml;r R, Fenner L, et al. Marginal and subgingival plaque--a natural habitat of Tropheryma whipplei? Infection 2003; 31:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/25\">",
"      Maibach RC, Dutly F, Altwegg M. Detection of Tropheryma whipplei DNA in feces by PCR using a target capture method. J Clin Microbiol 2002; 40:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/26\">",
"      Dutly F, Altwegg M. Whipple's disease and \"Tropheryma whippelii\". Clin Microbiol Rev 2001; 14:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/27\">",
"      Amsler L, Bauernfeind P, Nigg C, et al. Prevalence of Tropheryma whipplei DNA in patients with various gastrointestinal diseases and in healthy controls. Infection 2003; 31:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/28\">",
"      Fenollar F, Pu&eacute;chal X, Raoult D. Whipple's disease. N Engl J Med 2007; 356:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/29\">",
"      Fenollar F, Trani M, Davoust B, et al. Prevalence of asymptomatic Tropheryma whipplei carriage among humans and nonhuman primates. J Infect Dis 2008; 197:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/30\">",
"      Sch&ouml;niger-Hekele M, Petermann D, Weber B, M&uuml;ller C. Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 2007; 73:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/31\">",
"      Fenollar F, Mediannikov O, Socolovschi C, et al. Tropheryma whipplei bacteremia during fever in rural West Africa. Clin Infect Dis 2010; 51:515.",
"     </a>",
"    </li>",
"    <li>",
"     Dobbins WO III. Whipple's Disease, Charles C Thomas, Springfield 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/33\">",
"      Bai JC, Mota AH, Mauri&ntilde;o E, et al. Class I and class II HLA antigens in a homogeneous Argentinian population with Whipple's disease: lack of association with HLA-B 27. Am J Gastroenterol 1991; 86:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/34\">",
"      Olivieri I, Brandi G, Padula A, et al. Lack of association with spondyloarthritis and HLA-B27 in Italian patients with Whipple's disease. J Rheumatol 2001; 28:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/35\">",
"      Martinetti M, Biagi F, Badulli C, et al. The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple's disease. Gastroenterology 2009; 136:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/36\">",
"      Bentley SD, Maiwald M, Murphy LD, et al. Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whipplei. Lancet 2003; 361:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/37\">",
"      Li W, Fenollar F, Rolain JM, et al. Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 2008; 154:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/38\">",
"      Marth T, Roux M, von Herbay A, et al. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin Immunol Immunopathol 1994; 72:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/39\">",
"      Ectors N, Geboes K, De Vos R, et al. Whipple's disease: a histological, immunocytochemical and electronmicroscopic study of the immune response in the small intestinal mucosa. Histopathology 1992; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/40\">",
"      Marth T, Neurath M, Cuccherini BA, Strober W. Defects of monocyte interleukin 12 production and humoral immunity in Whipple's disease. Gastroenterology 1997; 113:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/41\">",
"      Marth T, Kleen N, Stallmach A, et al. Dysregulated peripheral and mucosal Th1/Th2 response in Whipple's disease. Gastroenterology 2002; 123:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/42\">",
"      Schneider T, Stallmach A, von Herbay A, et al. Treatment of refractory Whipple disease with interferon-gamma. Ann Intern Med 1998; 129:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/43\">",
"      Ectors NL, Geboes KJ, De Vos RM, et al. Whipple's disease: a histological, immunocytochemical, and electron microscopic study of the small intestinal epithelium. J Pathol 1994; 172:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/44\">",
"      Bai JC, Sen L, Diez R, et al. Impaired monocyte function in patients successfully treated for Whipple's disease. Acta Gastroenterol Latinoam 1996; 26:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/45\">",
"      Moos V, Schmidt C, Geelhaar A, et al. Impaired immune functions of monocytes and macrophages in Whipple's disease. Gastroenterology 2010; 138:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/46\">",
"      Maiwald M, von Herbay A, Persing DH, et al. Tropheryma whippelii DNA is rare in the intestinal mucosa of patients without other evidence of Whipple disease. Ann Intern Med 2001; 134:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/47\">",
"      Desnues B, Lepidi H, Raoult D, Mege JL. Whipple disease: intestinal infiltrating cells exhibit a transcriptional pattern of M2/alternatively activated macrophages. J Infect Dis 2005; 192:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/48\">",
"      Desnues B, Ihrig M, Raoult D, Mege JL. Whipple's disease: a macrophage disease. Clin Vaccine Immunol 2006; 13:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/49\">",
"      Desnues B, Raoult D, Mege JL. IL-16 is critical for Tropheryma whipplei replication in Whipple's disease. J Immunol 2005; 175:4575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/50\">",
"      Moos V, Kunkel D, Marth T, et al. Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple's disease. J Immunol 2006; 177:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/51\">",
"      Durand DV, Lecomte C, Cath&eacute;bras P, et al. Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Soci&eacute;t&eacute; Nationale Fran&ccedil;aise de M&eacute;decine Interne. Medicine (Baltimore) 1997; 76:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/52\">",
"      Lagier JC, Lepidi H, Raoult D, Fenollar F. Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine (Baltimore) 2010; 89:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/53\">",
"      Alzahrani AS, Al Sheef M. Severe primary hyperparathyroidism masked by asymptomatic celiac disease. Endocr Pract 2008; 14:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/54\">",
"      Vital Durand D, G&eacute;rard A, Rousset H. [Neurological manifestations of Whipple disease]. Rev Neurol (Paris) 2002; 158:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/55\">",
"      Mori K, Ando I, Kukita A. Generalized hyperpigmentation of the skin due to vitamin B12 deficiency. J Dermatol 2001; 28:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/56\">",
"      Riemer H, Hainz R, Stain C, et al. Severe pulmonary hypertension reversed by antibiotics in a patient with Whipple's disease. Thorax 1997; 52:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/57\">",
"      Elkins C, Shuman TA, Pirolo JS. Cardiac Whipple's disease without digestive symptoms. Ann Thorac Surg 1999; 67:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/58\">",
"      Cremniter J, Bauer T, Lortat-Jacob A, et al. Prosthetic hip infection caused by Tropheryma whipplei. J Clin Microbiol 2008; 46:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/59\">",
"      Louis ED, Lynch T, Kaufmann P, et al. Diagnostic guidelines in central nervous system Whipple's disease. Ann Neurol 1996; 40:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/60\">",
"      Matthews BR, Jones LK, Saad DA, et al. Cerebellar ataxia and central nervous system whipple disease. Arch Neurol 2005; 62:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/61\">",
"      Gerard A, Sarrot-Reynauld F, Liozon E, et al. Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Medicine (Baltimore) 2002; 81:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/62\">",
"      Panegyres PK, Edis R, Beaman M, Fallon M. Primary Whipple's disease of the brain: characterization of the clinical syndrome and molecular diagnosis. QJM 2006; 99:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/63\">",
"      Gubler JG, Kuster M, Dutly F, et al. Whipple endocarditis without overt gastrointestinal disease: report of four cases. Ann Intern Med 1999; 131:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/64\">",
"      Fenollar F, Lepidi H, Raoult D. Whipple's endocarditis: review of the literature and comparisons with Q fever, Bartonella infection, and blood culture-positive endocarditis. Clin Infect Dis 2001; 33:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/65\">",
"      Lepidi H, Fenollar F, Dumler JS, et al. Cardiac valves in patients with Whipple endocarditis: microbiological, molecular, quantitative histologic, and immunohistochemical studies of 5 patients. J Infect Dis 2004; 190:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/66\">",
"      Geissd&ouml;rfer W, Moos V, Moter A, et al. High frequency of Tropheryma whipplei in culture-negative endocarditis. J Clin Microbiol 2012; 50:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/67\">",
"      Mar&iacute;n M, Mu&ntilde;oz P, S&aacute;nchez M, et al. Tropheryma whipplei infective endocarditis as the only manifestation of Whipple's disease. J Clin Microbiol 2007; 45:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/68\">",
"      Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev 2001; 14:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/69\">",
"      Dobbins WO 3rd. The diagnosis of Whipple's disease. N Engl J Med 1995; 332:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/70\">",
"      von Herbay A, Ditton HJ, Maiwald M. Diagnostic application of a polymerase chain reaction assay for the Whipple's disease bacterium to intestinal biopsies. Gastroenterology 1996; 110:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/71\">",
"      Ramzan NN, Loftus E Jr, Burgart LJ, et al. Diagnosis and monitoring of Whipple disease by polymerase chain reaction. Ann Intern Med 1997; 126:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/72\">",
"      Fenollar F, Raoult D. Molecular techniques in Whipple's disease. Expert Rev Mol Diagn 2001; 1:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/73\">",
"      Fenollar F, Laouira S, Lepidi H, et al. Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis 2008; 47:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/74\">",
"      Pron B, Poyart C, Abachin E, et al. Diagnosis and follow-up of Whipple's disease by amplification of the 16S rRNA gene of Tropheryma whippelii. Eur J Clin Microbiol Infect Dis 1999; 18:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/75\">",
"      von Herbay A, Ditton HJ, Schuhmacher F, Maiwald M. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. Gastroenterology 1997; 113:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/76\">",
"      Fenollar F, Amphoux B, Raoult D. A paradoxical Tropheryma whipplei western blot differentiates patients with whipple disease from asymptomatic carriers. Clin Infect Dis 2009; 49:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/77\">",
"      Keinath RD, Merrell DE, Vlietstra R, Dobbins WO 3rd. Antibiotic treatment and relapse in Whipple's disease. Long-term follow-up of 88 patients. Gastroenterology 1985; 88:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/78\">",
"      Feurle GE, Marth T. An evaluation of antimicrobial treatment for Whipple's Disease. Tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci 1994; 39:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/79\">",
"      Marth T, Raoult D. Whipple's disease. Lancet 2003; 361:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/80\">",
"      Feurle GE, Junga NS, Marth T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease. Gastroenterology 2010; 138:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/81\">",
"      Cooper GS, Blades EW, Remler BF, et al. Central nervous system Whipple's disease: relapse during therapy with trimethoprim-sulfamethoxazole and remission with cefixime. Gastroenterology 1994; 106:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/82\">",
"      Schnider PJ, Reisinger EC, Berger T, et al. Treatment guidelines in central nervous system Whipple's disease. Ann Neurol 1997; 41:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/83\">",
"      Fleming JL, Wiesner RH, Shorter RG. Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc 1988; 63:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/84\">",
"      Schneider T, Moos V, Loddenkemper C, et al. Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 2008; 8:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/35/11833/abstract/85\">",
"      Feurle GE, Moos V, Schinnerling K, et al. The immune reconstitution inflammatory syndrome in whipple disease: a cohort study. Ann Intern Med 2010; 153:710.",
"     </a>",
"    </li>",
"    <li>",
"     Feurle GE. Whipple's disease. Orphanet Encyclopedia 2004. file://www.orpha.net/data/patho/GB/uk-WhipplesDisease.pdf (Accessed on January 10, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2702 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-118.195.65.248-57510F31CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11833=[""].join("\n");
var outline_f11_35_11833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CNS disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Endoscopy with small bowel biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Central nervous system disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immune reconstitution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2702\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2702|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/41/40600\" title=\"picture 1\">",
"      T whipplei electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/13/34006\" title=\"picture 2\">",
"      PAS positive macrophage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2702|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/22/37228\" title=\"table 1\">",
"      Treatment of Whipples disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_35_11834="Lichen sclerosus - trunk";
var content_f11_35_11834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74154%7EDERM%2F56113%7EDERM%2F82198%7EDERM%2F50218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74154%7EDERM%2F56113%7EDERM%2F82198%7EDERM%2F50218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen sclerosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oval porcelain-white plaques are present on the trunk of this patient with extragenital lichen sclerosus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized morphea on the trunk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isomorphic, hyperpigmented, sclerotic plaques are present on the chest and abdomen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pansclerotic morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sclerosis encompassing the majority of the body surface area, characteristically sparing the fingertips, is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fibrotic changes resembling cellulite are present on the leg in this patient with eosinophilic fasciitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11834=[""].join("\n");
var outline_f11_35_11834=null;
var title_f11_35_11835="Suggested apolipoprotein B or LDL-P treatment goals";
var content_f11_35_11835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested apolipoprotein B or LDL-P treatment goals",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        apo B, mg/dL",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        LDL-C, mg/dL",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Non-HDL-C, mg/dL",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        LDL-P, nmol/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td>",
"        &lt;80",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;80",
"       </td>",
"       <td>",
"        &lt;100",
"       </td>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        &lt;1100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;100",
"       </td>",
"       <td>",
"        &lt;130",
"       </td>",
"       <td>",
"        &lt;150",
"       </td>",
"       <td>",
"        &lt;1400",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Disease Division Working Group on Best Practices. Clinical Chemistry 2009; 55:407. Copyright &copy; 2009 American Association for Clinical Chemistry. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11835=[""].join("\n");
var outline_f11_35_11835=null;
var title_f11_35_11836="NCI CTCAE grading of neurotoxicity";
var content_f11_35_11836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCI Common Terminology Criteria for Adverse Events (CTCAE) for neurotoxicity, v4.03",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Toxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial neuropathy (any)",
"       </td>",
"       <td>",
"        Asymptomatic, detected on exam/testing only; intervention not indicated",
"       </td>",
"       <td>",
"        Moderate symptoms; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe symptoms; limiting self-care ADL",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motor neuropathy",
"       </td>",
"       <td>",
"        Asymptomatic, clinical or diagnostic observations only; intervention not indicated",
"       </td>",
"       <td>",
"        Moderate symptoms; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe symptoms; limiting self-care ADL; assistive device indicated",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sensory neuropathy",
"       </td>",
"       <td>",
"        Asymptomatic; loss of deep tendon reflexes or paresthesia",
"       </td>",
"       <td>",
"        Moderate symptoms; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe symptoms; limiting self-care ADL",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paresthesias",
"       </td>",
"       <td>",
"        Mild symptoms",
"       </td>",
"       <td>",
"        Moderate symptoms; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe symptoms; limiting self-care ADL",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADL: activities of daily living; NCI: National cancer Institute.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.03, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11836=[""].join("\n");
var outline_f11_35_11836=null;
var title_f11_35_11837="Drivers with ventric arrhyth";
var content_f11_35_11837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F51053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F51053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with ventricular arrhythmias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       Coronary Heart Disease (CHD)",
"      </td>",
"      <td>",
"       Sustained VT: poor prognosis and high risk",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NSVT, LVEF &lt;0.40: unfavorable prognosis",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       NSVT, LVEF &ge;0.40: generally considered to have good prognosis",
"      </td>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Cardiology examination required",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       At least 1 month after drug or other therapy is successful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by cardiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Dilated cardiomyopathy",
"      </td>",
"      <td>",
"       NSVT (LVEF &le;0.40)",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sustained VT, any LVEF",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Syncope/near syncope, any LVEF: high risk",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hypertrophic cardiomyopathy",
"      </td>",
"      <td>",
"       Variable but uncertain prognosis",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Right ventricular outflow VT",
"      </td>",
"      <td rowspan=\"6\">",
"       Favorable prognosis and low risk for syncope",
"      </td>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yes, if asymptomatic",
"      </td>",
"      <td>",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Recommend evaluation by cardiologist",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Evaluation by cardiologist required",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       At least 1 month after drug or other therapy successful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by electrophysiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Idiopathic left ventricular VT",
"      </td>",
"      <td rowspan=\"5\">",
"       Favorable prognosis and low risk for syncope",
"      </td>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Yes, if asymptomatic",
"      </td>",
"      <td>",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Recommend evaluation by cardiologist",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Evaluation by cardiologist required",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       At least 1 month after successful drug therapy or ablation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Cleared by electrophysiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Long QT interval syndrome",
"      </td>",
"      <td>",
"       High risk for ventricular arrhythmic death",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Brugada syndrome",
"      </td>",
"      <td>",
"       High risk for ventricular arrhythmic death",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EF: ejection fraction; LV: left ventricular; NSVT: nonsustained ventricular tachycardia; VT: ventricular tachycardia.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11837=[""].join("\n");
var outline_f11_35_11837=null;
var title_f11_35_11838="Clinical COPD Questionnaire";
var content_f11_35_11838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F86308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F86308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical COPD Questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"30%\">",
"     </colgroup>",
"     <colgroup span=\"7\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"subtitle1\" colspan=\"8\">",
"        Please",
"        <em>",
"         circle",
"        </em>",
"        the number of the response that best describes how you have been feeling during the",
"        <em>",
"         past week",
"        </em>",
"        .",
"        <br/>",
"        (Only",
"        <em>",
"         one",
"        </em>",
"        response for each question)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        On average,",
"        <strong>",
"         during the past week",
"        </strong>",
"        , how often did you feel:",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Never",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Hardly ever",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        A few times",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Several times",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Many times",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        A great many times",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Almost all the time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Short of breath",
"        <strong>",
"         at rest",
"        </strong>",
"        ?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Short of breath",
"        <strong>",
"         doing physical activities",
"        </strong>",
"        ?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.",
"        <strong>",
"         Concerned",
"        </strong>",
"        about getting a cold or your breathing getting worse?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        4.",
"        <strong>",
"         Depressed (down)",
"        </strong>",
"        because of your breathing problems?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"8\">",
"        In general,",
"        <strong>",
"         during the past week",
"        </strong>",
"        , how much of the time:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. Did you",
"        <strong>",
"         cough",
"        </strong>",
"        ?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        6. Did you",
"        <strong>",
"         produce phlegm",
"        </strong>",
"        ?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        On average,",
"        <strong>",
"         during the past week",
"        </strong>",
"        , how limited were you in these activities",
"        <strong>",
"         because of your breathing problems",
"        </strong>",
"        :",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Not limited at all",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Very slightly limited",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Slightly limited",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Moderately limited",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Very limited",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Extremely limited",
"       </td>",
"       <td class=\"centered sublist1_start\">",
"        Totally limited/or unable to do",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7.",
"        <strong>",
"         Strenuous physical activities",
"        </strong>",
"        (such as climbing stairs, hurrying, doing sports)?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8.",
"        <strong>",
"         Moderate physical activities",
"        </strong>",
"        (such as walking, housework, carrying things)?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        9.",
"        <strong>",
"         Daily activities at home",
"        </strong>",
"        (such as dressing, washing yourself)?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10.",
"        <strong>",
"         Social activities",
"        </strong>",
"        (such as talking, being with children, visiting friends/relatives)?",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CCQ Questionnaire calculation of scores:",
"    <br>",
"     <ul>",
"      <li>",
"       CCQ total score = (item 1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 + 9 + 10)/10",
"      </li>",
"      <li>",
"       Symptom = (item 1 + 2 + 5 + 6)/4",
"      </li>",
"      <li>",
"       Functional state = (item 7 + 8 + 9 + 10)/4",
"      </li>",
"      <li>",
"       Mental state = (item 3 + 4)/2.",
"      </li>",
"     </ul>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: van der Molen T, Willemse BW, Schokker S, et al. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003; 1:13. Copyright &copy; 2003 Thys van der Molen. The Clinical COPD Questionnaire is copyrighted. It may not be changed, translated, or sold (paper or software) without permission of Thys van der Molen. The CCQ is available for all clinical purposes without charge in 62 languages on",
"      <a href=\"file://www.ccq.nl\" target=\"_blank\">",
"       www.ccq.nl",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11838=[""].join("\n");
var outline_f11_35_11838=null;
var title_f11_35_11839="Pruzansky classification of mandibular abnormalities";
var content_f11_35_11839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pruzansky classification of mandibular abnormalities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 367px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFvAXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiisbXdVvtNlhNrpE9/bsCZHhkUNH/wABPX86ANmiuQi8fadvK3thrFjjq09k+Onquamj8feHJFLLfS4Bwd1pMP5pQB1NFctbeP8AwxcGQQ6rGxQZbMTjA/FaZJ4/0LKrave3kjchLezlYn8SoHb1oA6yiuMj8a3d4CNK8La1MR3uES3H6k/yqRJvGt83FvpGlxHoXZ7hx+A2jNAHXEhQSxAA5JNR21xDcx+ZbTRzR5I3RsGGR15Fct/whaahhvEupXmrnr5UjCOEH/rmuAfxya6XT7G1060jtbGCO3t4xhY4xgCgCzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzet6vrWlag7pov8AaGlYB32sg89OOco3DfgRXSUUAcHqPxW8H2NuzXuoPFcLgCzktpFnZjwFCFeSTxxxUA+JFhavbtr2gato9lcMFjvLqBfKGTgbypOzPvxWp8T9DbV/CN6bGCN9StSl5bfKMtJEwcL+O3H41paTc6f4x8I2880KXFjqFuPMikGQQRypHr1oA1kgtnQPHFCysMghRgiob290/S4xLfXNpZx9A80ixj8zivC9P0PxF4I8Uv4dTxjfadpF4/8AxKJ54UngC/8APAlx8kg7c4I969M0/wCHWj+f9t1/fr2pnrdahh8eyL91R7AUAddZXltfQiayuYbmE8B4XDr+YqevP9W8IDw08mueBLRbe9jG6fTYm2Q3iDqNvQP6N+ddP4T8RWXibR4r+wYjPyywvxJA4+8jjswNAGzRRRQAUUVTuNTtLfUbawllAu7kM0cYGSQvUn0HPU0AXKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuZ8Raj4nt9RSHQdFsru12bnuLi7MeG9AoU/nmgDpqK4KbXvHlpveTwjYXcagYW21La5+m5MfrSWfxO02G5S08VWN94avHxgagg8lj6LMuV/PFAHfUVHBNHPEksEiSROMq6HII9QakoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK898KAeFfHWpeGsFNN1ANqWnZ6KSf30Y+jHcB6NXoVcZ8UdFudQ0OLUtJQnWtHlF7Z7erlfvx/R1yPyoA6LXtGsNf0ubT9WtkubSUYZG7HsQexHYiuNh0Hxp4aQweHNWs9W08DEVvrAbzIh6CVTkj6g11/hjW7TxFoNnqunuHguYw4/2T3B9CDkVqUAcBH4N1XxCDP441WR933NP02R4IIvxB3OfcmuQ03wdd6X8QNSsNF1m6sNUW3S6tbxl81biAkr5c6nhypBAb72Mc17dXnnjy4j0Px94Q1u4lENpM02mTyM2FBkAaPP4qw/GgCcan8QNNG270LSNYUceZZ3bW7H32urD9aIvHt/au/8AwkPhHWdOhBx9oi2XUePU7DuA/wCA13YIOCOlKRkYPSgDjJfiX4WazMunapDqNyRiOztTvnkb+6E6j6nAHerfhLRriO6udd1oA6xfAZTqLaIfdiX6dz3Oa2oNI063vWvILG2jumGDKsQDH8avUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWZ4oupbHw1qt3bMEngtZZEYjO1ghINadQ3tul3Zz20gzHNG0bA+hGDQB5P4T+HS3XhrTtY03xLrdrrd3Ak8l6l20iSuRnLRsSpHtirr+JrjSD/YvxUsbaS1m+SPV0hzaTA8YlB/1bfpWh8DbuSTwFBp9zgXekzS6fMv90xsVH6Yru7u1gvLd4LuGOaBxhkkUMp/A0Aear4eufDscmpfDC+gubTd5kuitOHt5R38pufLb0xx7V2PhDxTY+J7F5bUSQXULeXc2c42y2791Zf5Hoa5/UvhL4UuElfT7D+yrxhmO5sXMTRP2YYOMg1zNnaarqNi3iLSFRPG+hytY6jAp2pqKoeVftllwyntmgD2Wisfwpr9r4k0WDULPcm/5ZIXGHhccMjDsQeK2KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPMvCYbwf8AEnU/DL/LpOrBtT03PRHz++iH4kMAOxr02uF+L2mzzeHI9Z01N2q6FMNQg28FlX/WJn0ZNw/Kut0XUIdX0m01C1cNBcxLKhB7EZoAu1wnxs0eLV/h1qIltxcfYmS+ERGd3lsGYfiu4fjXd0yaJJoZIpVDRupVlPQg9RQB5tpk3ibw3pVrNosI8TeH5I1khj87ZdQoRkKGPEgHbOD7mtJfiVp0IH9qaVrunADLvPYsUT6smfzqD4aPL4evb/wZqDnNixm052P+utGPy490Pyn6D1ro/Hk8lr4L1yaBS0iWUrKF6/cPI+nWgDIT4oeEJEWSPVy8J6SrbTGP/vrZj9a6LTfEGj6myLp2q2N07Dcqw3COSPoDmub8Maj4e0r4eQTQ3NnLY6fYLLMEdGKqEz8wHc1z/wANfAvh3V/h/pt9qGk2r3Wor9teZU2OrOdwww5GM4FAHq9FeUaFoOq6rrmtab/wlesxaPpMy28EccgEpYoGO+TG5gNwA5+tXra98V6B41t9C+0Q63pk9v58ct0fLuEAbaw3AYfGQeRnmgD0migZooAKKKKACiiigAooooAKKKKACiiigAooooA858NqugfFvxDpWNsGswpq0GO7j93KPzCn8a9Grzn4uRvpl14a8Vw5/wCJRfCO5wcA282Ecn2B2mvREcOispyrDIPqKAHV5/pwbRPi/qlvIdtrrtpHdQjt50XySD67dhr0CvP/AIvxvp9jpHiiFCz6DdrPKACSbd/klAx6Ahv+A0AL4p8OatpWqSeI/A+z7e5BvdNkbbDfAdT/ALMmOjfnT9H+Knhq7m+yarcvoeprw9pqamBge+GPysPcGu3tp47m3inhYNHIodWB6giq2p6PpuqxGPUrG2uk9Jow386AKGteK9I0rQ7jVHvILiCJNyrBIrtIx4VVweSTgCsO3n8eXVgl+iaLbvJ866fKjllU/wAJlDY3e+3Fc78QvAHhnSLCw1TTfD8EJtdQt5p5LaL5o4w+S20dQDjOO1dvB438Ny3AgGr28UhIC+eDEG9gXAB/A0AXvC+tR69o8V6kbQSZaOaFz80UinDIfoQRWtXGfDy4gu7zxRPYj/Q21RxG6nKOQqh2U+m4NXZ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADXRZEZHUMrDBB6EVwfwtSXRpdb8K3B+XS7kvZ982snzR/lyv8AwGu+rgvG7NoXi7w94jVyltI/9mXo7FJDmNj9HGP+BUAd7RQOnFFAHNeNPDZ12C2ubC4+xa1Yv5tndgZ2nujDujdCK4jxp4yS48IajoPiJP7I12VUgeOQkRXAZ1DGGT+IEE8dRnpXrlZfiPQNM8R6XNp+s2kVzbSqQVccr7g9iOoIoA8s8Y/Bbwu2lXeqaV5ujTQ2nmOlqcQS+WNw8yM8EZUZHeua+HjfEq98NC48FXunQ6LFKYre11Bd7Ls+V1VgOEDAgDqBXo2reE/Fk3h+bw9Y+IbX+y5ovs5urm3Z7pYjwVDBgpOOMkE81Q8Ayr8MdGPhzxKZxbxTSzQaosJMMyuxf5toOxhnGDx6GgDhdM8QeN/hx4o1NNf0y01i915luo7e1udm6cnZtQFemAOD2BOa7bwT4lm8S+L7S88Sw22h6rYwS2qabJIRM7uw3Hngr8gxjOeawLjW7fXvj54c1GW3nh0lLaa3sLm4iMaXEmAcrn6sB64r0X4rW8UvhSVI41/tCeeGK0kVfnWUuMMD14AJ+gNAHZ0VHbq6QRLIdzhQGPqcVJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBn6/pcGt6JfaXdjNvdwtC/sGGMj3HWuZ+Eury3/hltPvpC+qaNM2nXeepePgN+K4P4121ec3jjwr8W4Jz8mm+JofJc44W7iHy+w3J+q0AejVX1Czg1CxuLO7jElvcRtFIh6MrDBH5GrFFAHnvwlu5tOhv/B2pOTfaE4jiZv8AltatzE4/4DwfcV6FXD/ECwuNPu7XxfpEJkvtNUpdQouWubUnLL7sv3h+I71buvFc17Lp0Xha2g1Fru2N55kkpSNYxgAZAPJOR7YNAHWEAgggEHsaq3mm2V7A0N3aQTRHqjxgiuXbx/Z2W2LXNP1PT7lR++H2Z5Yov9oyKNu33/PFdVFf2kskccdzC0kieYiBxuZfUDrigBNN0+z0uzS0062itrZM7YolCqM+wq1RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYvjLQ4/EvhfUdJlO37TEVR/7jjlG/BgD+FbVFAHMfDrWJtY8L2zXy+XqVqTa3kfdJkO1vwOMj2NdPXnGty/8IR4+TWXJXQdeZLe8b+G3uQMRyH0DD5SfUCvRgQQCCCD3oAWiiigAprosilZFVlPZhkU6igDO1rRdO1uwNlqdpFPbZyFYfdPYj0PuK5OT4cQR39he2et6ys9jKJIFnumnjUdCux8jkEj1Fd7RQAg6c8mloooAKKKKACiiigAooooAKKKKACiiigAooooAK5r4ieG/wDhKfCt1YRP5V6mJ7ObvFOhyjfmMfQmulooA5f4c+I/+El8L211Ooj1CHNvew94p04dSPrXUV5n4iEngLxk/iWCNm8O6sVj1VV/5dpRwlxj0PAb8DXpUUiSxrJGwdHAZWHIINADiMjB6V4/q2l3Hw08Zf8ACSWInm8IXKsl9aRjd9gZmz5yjrsyTlR0yTXsFI6K6MrqGUjBBGQaAOd8R6nY33gHV9Qs7uCazk0+Z0nRwVI8s85rgvhd4U07xF4PXU9VtmGqzTvsvEk/eoqNtjKsOgAA4rrtR+G3he/d/O07ZDI26WCKRkil/wB5AcH8RWfYW158P3u7PS9ElvfDjyNPbpZEeZbMxyybCRldxJGDxnHagCrrQ1zwjq+gXs3iK91O0vb9NPmtZ4YwoV1Yqy7VHIK9e+a9Mrz9BqnjPWtJnutIudI0jTZ/tY+1Mvm3Em0qo2qTtADHqa9AoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigChruk2euaRd6ZqcKzWlzGY5EPoe49COoNee6Vq198N549H8Vzy3XhxmCWOsuMmEdopz2x0D9D3r1Gob20t761ktryGOe3kXa8cihlYehBoAdbTxXMCTW8qSwuNyOjBlYeoIqSvMp/h3qXh+aW4+HWuSaUrtvbTLlfOtCe+1TymfY1Lb+LvG9gxh13wM90w/5eNKu0ZGP+6+CPzoA9Iori08c3IiD3PhDxLDgfPiGFwv5SZP5U+D4j+HfNSHULm40qdzgJqNu8Az/AL5G39aAOxoqGzu7e9hE1nPFPEejxOGU/iKmoAKKKKACiiigAooooAKKKKACiiigApCM8c0tFABRRRQAUUUUAR3MEVzBJBcRpLDIpV0cZDA9QRXmlpfzfDPU00zV3kk8IXMgSwvG5+wMf+WMp/uZ+6x6dDXp9VdTsLXVLCey1C3juLWZSkkUi5Vh7igCyrBlDKQVIyCOhpa8siXX/hkGjjhudf8AB4bKKnz3enp6Af8ALRB27gfSvQPD2vaZ4i02O/0W9hu7V/4oz0PoR1B9jQBp0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRTJpY4IXmnkSOKNS7u5wqgckknoKy9O8TaDqV0ttp2t6Xd3LAlYoLuORyAMnABzQBr1DdWtvdxlLmCOZCMFXUMP1qaigDjbvwDp0M/wBr8Nyy6FfjpJZ8Rv7PH91h9RV7QNR1tL3+zvEOnr5gUmO/tTmGXHqp5Rvbke9bl/e2mnWkl1qFzBa2seN808gRFyQBljwOSB+NN03ULLVLYXOmXlteW5JUS28qyJkdRkEigC1RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFV7+9tdOtJLrULmC1tY8b5p5AiLkgDLHgckD8aq6Vr2j6vJJHpOq2F88Y3OttcJKVHqQpOKANIjPWuL1zwBaXGoyar4fu7jQdYcfPcWeAsv/XSM/K/4iu0ooA4iPV/FegxKNe0yLWbdR813pfyyY9WhY8/8BP4Va0z4h+Gr+aKA6h9ju5CFW3vYmt5Mk4Aw4H6Vv6rq+m6RHHJq2oWdikh2o1zOsQY+gLEZrPk1fwxf30Fo+o6NcXkmx4oTPE0jZAZCozk5BBGOoINAG9miqtrqNjdXdxaWt5bTXNsQJ4Y5VZ4s9Nyg5XPvVqgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk0Uc8LwzxpJFIpR0cZVgeCCD1FeHaT8PpbYfFOSGyXQZ7idn0fUYALdoVEWQ0ci4KJuGCARkZHevdKbIiSxtHIqujAqysMgg9QRQB8yR654l1HwF4Y8Uaxe62JfEfie2Q2On3kkR+yLBKnlRgMu3eULnBGSVPUA1d1Dw/8AEN/DujoTriaN9tv3a1Ezz3sEDkfZRLsuIncqN3HmHGRkNjA+iTZWpigiNtB5duQ0KeWMRkDAKjsQOmKnoA87v7TUz8Dp7HU7XUdY1V9Ma2Mc0CfaZpGG1GdN7KGBKsfmOME5Jq78FrOfTvhnoNhe6ZPpt5aWyQTwzRhGMigBm4JyCe/U129FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAV7+ytdRtJLXULaC6tZMb4Z4w6NggjKng8gH8K+eNO0DUvAfwFOtJanRvEGkaidQlUMIGu4VuT+4lZfvIyNwpyM7eK+j6iureC6gaG6hjmhbG6ORQynByMg+4FAHzhqQ8RWh8Fafrdx4o1O91TStQvryy0+/ljkM7lGjX/WLhY9wUDOBg8YzS+IPDvxNdNGTUr7XC0ekQIlxpeZ5IbtSTJvAuYVLEbQXcSKeenWvo5reF7iOd4Y2njBVJCoLKD1APUZqWgDyj9oXS9Q1z4dQ6fYaNdapqUlxA4EESt5Wx1ZycnjIBHGfSsm9t7lPjZpviK18G6p/ZtvoP2fctpGuJziRF4bgquI89iMDjmvbaKAPnb4XeFPG/hj4g6T4j1jS4mTxDFOusG2uHkeJ5HM0byoygIVJEfys3APSvomiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb+H2q/214Yt70ztPveQb268MRj8MV0lcd8I4jF4B0wFSpIdsEY6sTmuxoAKKKKACiiigAooooAKKKKACiiigArntM1e4uPGetaVJt+z2kMEkZxz84OR+ldDXE+HGeT4oeLiQPLjhtIhjqT5e7/2agDtqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDkPhPdNd+AtKkfGQhQYGOAxArYk162j8Uw6Cwf7XLam7U9tobaf1rnPg6fK8K3Nk20PZald25VSSFCzNgc+2KTKzfGolVBNvoqqzehaVjj9KAO7ooooAKKKKACiiigAooooAKKKZMxWF2XqFJFAD+a4fwZKbjx745lVlMSXUEI45DLAma1Ph7KZ/CVlM1w1w0gZ2kbuSxyKyfhbN9rl8VXm1dsus3Cq4/iVDtB/SgDuqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDz74XCS31zx1ZzHmPWnlRf9mRFcHH/AqteFmS68feL9QBXZC0NmWPYom4/q1UdEI0740eKIH+VL+wtrxcnqV3Rt/6CK5ISXjfDFGU+Xc+LNZbe24qRBI7OcHOf9Wm38aAOg8Q+ONf1yVrP4b2UEsKyeTNrN5nyEOcHygOZCPXGKzz4Z8Y2atcReP9T+3tgqlzDFJB75THA64weldjYadFYWEMFiphs7fEcaxjGAABxn6Yz7k5q/vm8tSxEhY9A3UeuSfcZ+lAHG2Pj7xB4fnWHx7pMf2AnaNX04ExLzjMkZ+ZRxyRkCvT7aeK6t457aVJYJFDo6HKsD0INYN5BC0ZaSIOmzDB8YYYHU5xjk+vWua+FVwbDWvEvhhd32XT50ntAcYWGUZ2rj+EMGA9qAPSKRiFUsxAAGST2pa5b4pXRs/h14jmVyjCxlUMDggsu3+tAHN33j/Vdfvbix+HunQ3McD+XLq16xW2BBwRGBzIR68DIrPXR/GpNzcav42uFkCZENpaJEinnnkHjj/6/NdD4O0+DTfC+m2dsq+XBaxxqExwygZJPTOTW2YDuz9oLMpO7AHy+3t16+1AHn8OrfEHwxKZbqW38UaWCNyeUIrpV77dvDHrwwHTGa9Q0HV7LX9Ig1DTZRLazrkHGCPVSOxHQispZDJl2DJHHjJU5KkEZz/P8+tcz4Hh/wCEf+I+uaJCyiyv7dNTijXojklJPbkqD260AanwtmW08I3UMjHFjd3MbA9VCyNgflT/AIOwLF4CsZV3ZumkuSW6ku5b+tcpqmpp4a0n4qoGIeFmuVyehniXGP8AgTV6L4IsP7M8H6NZYx5FpGmP+AigDbooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPH/jNbamfF/hweHCh1LVILjS5hnmOBtpaX/gI3YPqRVv4rw23h/R/BZMTtZWOpww4Q9Mxui59s1tWAjk+M2rGZsyxaTb+QGPQNJJux+QzXSeK9AsvE/h+90jUkLW10m0kdVPUMPcHBoAzIGDIqADbgsScHB4wOOnOe3apka5ih2bQCw+Vlbd+nfp+hrzxZvGXgq3Frq+kTeIbGJdseoaaV80KPulom/ixkcH8Klh+IU+oW+bDwh4qkfdt8qS1EIYY6ZZsDvzigD0R9syDa4BB/eAfxEDA4Hbj2rj/h3G118S/GmpwsklkFtrJJUfcGdFJYDtxvA47g1DDa+OvE9uIzDF4UsZGO92kFxd7OwHG1Dz15xitPxKLP4c/Dc2GgoIZpCLKz3Ny08pxvZu5GSxPtQBn678SNXN9qLeE/D66tpelsyXVzJP5ZldfvrCMfMV7k8Vf+IN1b+LPgtrF5pim4hu9PM8agcnADYx6jHSsmO50/wdb+HtEMfnC43Wu7Ocuq7iTn1bPNW/hYjaNq2v+Frp/Mtw/wBvtEZcAQzZ3IB0wG3DigDY8L6pa6t4b065s1V4bmGOQleA3HP4jHStRlIuJSzKqtwqgdupJB479a4HUfhdq+gXcl38N9a+wQSSmWTSbwGS1Zj1291qE+NvE/h+5dPF3g+9jg3DF1pZ+1RdMH5PvAZx+FAHpsKssb8MoY9ABgcetcVz/wALt0iNDgro0zOFbAI80AHb+dU7X4teDJ2jiOqXC3SDHlG2m80nHK7duc8+vWrnw1tr7XPFereMdSsJ7CGaFLLT4Lhdsnkrks7DsWYnigDifjPbXVn49SxEDNYeLJbC3ebGEUwyEupPqVC49a+gYkEcaIvCqABXI/Fy0hu/hzrxmADQWr3ET945EG5WHoQQK3fDF0994d0y6l/1ktvG7fUqKANOiiigAooooAKKKKACiiigDhfHn27UPFHhvQ4NSuNOsbwXE1w9tL5csvlhMIrDkffJOPSo7vTvF3hlzPoN43iDTxy+n6hJicD/AKZzdz7Nn6074u2d2ujWOv6TEZdR0G5F6sajLSRY2yoPqpz/AMBFddomp22s6Ta6jYSLLbXMYkRlPUEUAeOeFNV8Ra7qPiG7006xb3UF/Ij208wDwhgGRfKcFCoBAyPTitW+8Y+MNF8Q6bod5Dps0+pRNPDPOpj8oIMurhCQx6Yxiuu8ReH9STWxr3he5hg1IoIrm3nB8m7QdN2OQw7MK898cReLL3xp4Z8SXXh4W+neH3Zrow3HmySrINrFFAyQODg88UAbGmfFW5uZLpVsdO1H7I5SZdNvCzjAyxCuoBwO2ecVv3/xO0C1ubS3hea7muIVn2wKDsU9AckfMf7vWnW3i/wTJDL5V/ZWiSA7nnhNupOOfmdVBPtnNcd8B9M03VvCOvWt/bQ3VvJqc2Elj6x5+Q4POMYxQB6Z4d8V6L4iLppN/HNMgy8JBSRfqpANbleVf2Dofgjx54d+w3C2FobW6Di5uzsVcx4C7zwMnoK3/FOpXms6tp/h/wAO3xgW4Q3N5fWzBmhhBwoU8gFjkZ9AaAO2orkPh1e30kOsaZqdzLeS6VfPapdS43ypgMpbHcBgCfauvoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDjvHfh2/u5rbXfDMyQeIbBCsYcfu7mMnJhf2PY9jWj4I8Sw+KdFW8jhe2uY3aC6tZPvwSqcMh/H9K6CvPPECXPg7xg3iGzs5rnRNRQR6nFbRl5IpV4SYIOSMcNjngGgD0Oiub8M+N/DviaeSDRtUhnuYxl4GDRyr/wBgD+ldJQAV5h8VEfUfGvgbS0I8tbia+lUjIPloAvH1c16fXlfjBpG+Nvh1Am5I9JuJVbBOGMij+VADPG0dqmt+GGmkSKZLqSVZc7gBsCkfX5hyaNXuV0fxZ4c1wFmheY6dcOVOWWY/KT9HUD/AIFVXxlvudRjcR4+yQRzgjlVzcKuceuASfWrfxWAi+H2pebJi6d42tymATMXGzb+JH60AerUEZGD0qCx3iyt/N/1nlru+uOanoAg+x2wfeLeHf8A3tgzU/QVW1C/tNOtmuNQuYLWBeskzhFH4mvOPHHxY06w06SHwqW1fVJWSGOSBC8EDOwRWkf7vVhxnJoAl+Jmrf8ACQ3f/CAaIWkv75VOoTIMrZ2pPzFj2ZgMAe+a9FtLdLW1ht4uI4kCL9AMVz3gPwrb+GNMcbjcandt599eOPnuJT1Y+3oO1dPQAUUUUAFFFFABRRRQAUUUUAIwDKQwBBGCDXlj2998Lb6abTLSa+8FXEhlmt4Rul052OWdB/FHnJIHI7V6pSEBgQwBB4IPegCrpeoWmq2MN7p1xHcWsyhkkjbIYVb69a831DwNqWganNq/w8vI7OSZt9xpNxk2lwe5A6xt7j8qnT4m2mmIU8aaXf8Ah6dfvPLEZrc+6yoCMfUCgDuZ7G1nj2T20MiddrICKw9Y8GaPql8Lx457W7CBPOs53gYqOgJUjOPepNO8aeGdSx9h8QaXMcZ2rdJnH0zmtU6lYgZN7bAeplX/ABoA5XTPh1pcGpyX+rXF7rlwQUhOpSecLdT1VAema5uxF54J8SeKBp3hO5updQmR7BrJVWFkCKNrsSNmG3E8d67XUPHfhXT9wvPEWlRlTgj7ShI/AGufufirpV1+48KWWo+ILxyUQWtu6wg+rSsAoHuM0AP+Fb6hZ3Gu6Tr7QSa1HcfbJ5YMhXEw3D/vnlf+A16DXJ/D/wAP3mlQXuo668UuvapL5920WdicYWNc/wAKgAfrXWUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVh+N9UfRvCmp30Lqk0UWEdhkKzEKCR6AkVuVzHxOtjdfD3xDEq7ibKRgMZyVGf6UAeXa14BurXxJpv2bVLia+ubdruwvrh8yQ3seCUz3jkVuV6cHFeqeA/E6eJ9EE8kTW2o27GC9tH+9BMPvA+3cHuDWP42USeC9J1m2JL6XJb3ysp5EYG2T/AMcZvyrlNcvnT4mX17oVz9huV08XEsgAaK7QIpQMp4JLMRuHIAoA9nrj/G3hO61rU9N1XSL9LHVLEPGGli8yOWN8bkYZB7DkEVQi8ZavpwlbXNJWWCEQpJNZMS3mSAEKEPXG4c571u23jPQpWeOe+jsrhDiSG6PlMhPQHPGT255oA88v7Lx1pz6pavodjqZ1K3Fna3NnOYktvlOXkVskDJzwT0rpvDXgSfz7PUPGF8uqajbYaGFE2W8DY+8qd2/2jz9K6ifxLo0Cgyana5JxtVwzZ6/dHP6Ulz4n0O3t/Pl1WzEWA24ShuD04Hr6UAbFUtZ1GDR9Ju9RvG229tE0rnvgDOB7noK5vVfH+nWm+O1t7y7uEeOJlWIqqM/3AzHpnIP41wHiXWtZ17VdNi8RfZdM0SLUFWXT1JZ7hkk2gO5xwG2MABzn2oAr3+j3Gv8AjLwXeeJw01/qNzLefYXJaK0tkT5Y9vTOWUknOTXZfEaOGXWvB/hyzt0RbzUBdTrEgG2KBd2SPTeUq7oEP9s/ETVdawDZadCNMtGHdgd0pH/AsL/wGoPDKnWvif4i1iQEw6YiaVbZ7HG+Qj6swH4UAegUUUUAFFFFABRRRQAUUUUAFFFFACZG7GefSloxzmigApk0UcyFJo0kQ9VYZFPrx3TvEXj4/ErV/D899o13BpVpHfukNg6SXKMTiJSZCFbjG45HPSgDtdS+HHg7UpPMvPDmmPJnO/yFDfmKrW3wt8F2zs0egWeSMHcuePxrmI/jjpVz4fv9Y0/Sru6tLCys7i52SKDHNcTCIW/P8S8knpxU2qfGSDSRqNnqehXMGuWmow6eLL7QjKxliMqOZQMBdgJOASDgc0Adxpvg3w3pu37BoenQFehSBR/StyKGKFdsMaRr6KoArmvCHiSbxl4PbUbG3l0i9k82BUu4vMEMqkqGwCu9M4YYIyO4ryKP4j+OJPhZYeKhqOjCe51b+zzB/ZrbVUymINnzuuQW6d8ds0AfQtFeZWmveKE+NkPhO61LTZdMXRRq8jJYMkjnzPJMYPmkDLfPnBwPlwfvV6bQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUF/ALqxuLdgCJY2Q/iMVPRQBxvwylGq/Dyxt75fMKRPZTq/8RQlGB/KvP9b8KHw6Ta6/E1/4ahnM9tdMebWJYSFjbuMMBhvpXceAGSw8S+LtEClPIvRdoOxSZQ/H4k1280aTRNHMivGwwysMgigDxWzvtShtreJ7kapbxpa6xdTnCzeWxZVQADDY2D3q3Lq+i6pZSR6gyWl5qOsLJNBfoIZBEjfIcN1GEQZBPWtjWvh/PYf2peeFJwJbu2S3NjdMTCFRiyhCOU5Le3PSqeua3p9wNcTWrI2bJo7RxteQbB5m19yK54J6EYNAHSeRp/8AwspGVbbzV0zPG3ODIef0rkb5vD1lpXipWmsBcLqgnSOFlZ3dWVlUKOSeOgq/d6H4Jli8Ms+maVI164jjlAX5h5ZJGe4NZ99DoeiDVl0y2tkl/tS2WOKzjDyYVkLYVcnAGc0AM8QawNe1W+tfD9rPL/atvDZrcvGYoo7qNnc7twDZChe3bFcZdaRfeK9fthBeNd+ILyGKd3T/AFGnRn5S6r0Dfu1xnkk56V6JYaP4l1a7E8MEWjWq6jPexyXH7yZlcMF+QcKcMTyT2rtfB3hXTfCelrZaXEQD80krnc8jepP9O1AF3QNJt9D0e20+0GIoUxk9WPdj7k81zXwlhCeHLy5KbXu9Su52Oc5zK2P0xXTeINQj0nQtR1GYgR2tvJMc8fdUn+lY/wAMbWW08BaHHcpsuDbI8q4/jYZP6mgDqKKKKACiiigAooooAKKKKACiiigAooooAKyrbw9pdt4ku9fhtdurXcKW80/mMd8aHKjaTtGPUDNatFAHlI+DtsPh34h8NLqaJc65qP8AaNzex2m0A+ekoRYw/CgIFHzcZJ9q6dfht4TGjzaYdJD201yL13e4leYzgYEnnFvMDAcAhsgHiuvooAx9O8N6bp2hT6RaR3KWU6usm67meU7xhj5rMZAffdkdiK5f/hT3gn+yI9KGl3Y06Oc3KQDVLvasn94fveuefrz1r0CigDlLX4f+HLXxRD4ihtbv+2YoRbrcPqFw/wC7AwEKtIVK98EHJ+brzXV0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcN4px4f8AG+k+ISmLO9QaZev/AHCSWhc+24suf9oV3OfyrP17SbXXdGu9M1BC9tcxmNwDgj0IPYg4IrldC1u78N3dvoHi2TIOI7HVDwlyOyueiyY/A9vSgDuqjmginTbNGki+jLkVIOeR0ooA56bwX4bmkDyaLYs4O5T5Q+U+o9DVvSPDuj6PNLLpmm2trLL994owGb6mtaigAoormPFnic6ZLHpmkQi+8QXKnyLUHhB/z0lP8KD9egoAx/iI8niDVNO8HWZytw63epOBkR2yNkKfd2AH0BrvY0CIqIMKowB6CsDwb4ebRLKSW+n+2axdt5t7dkY8x/QDso6AdhXQ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVPV9Ms9Y0+ax1K3juLWYbXjcZBq5RQB5tcXet/DtF8+O513wqpx5iAvd2S/7Q/5aIPX7w967XR/EGkazYreaXqVrc2xXdvjlB2j39Poa1CAQQQCD1Brlr34f+E72Z5bnQNPd3Ys7eSBuJ6k0AaR8TaEspjbW9MEmcbTdx5z6YzSy+JNDitjcSaxpywD/AJaG5Tb+eayB8NvBgII8M6VkdD9nXNTweAfCkDxtD4f01DG25cQLwfWgDCn8aaj4nZ7T4f2nmx/dfWLuMrbxj1jU4Mh/Ie9dF4R8K2nhyKaRZJLvUrpt93eznMkze57D0A4Fb8UaRIEiRUQcBVGAKdQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEN5bpd2c9tKXWOaNo2MblGAIwcMOQeeo6V8/eEdH1O11D4m3Hh7UtVm1bQblotKiu76a4jx5W7YyMxDk8gE9CQe1fQ9RXdvHd2s1tOGMUyNG4VipKkYOCCCOD1HNAHgP8AwtfX7/wppvihbq00bRtX8QwabbtcwB/ItRC/nSEkjP7xGxnpsqlqHxR8Yx+HdHlF3bW9jdXt/AniCW2WOO5iiIED4f5IxJluo528YOa9uj8F+H49I0PTI9OVbHRLiO6sIllceTKgYK2d2W+833ic5yc10VAHmeva1/aPwDu9X8RXsFtPJphke5s7l4U88f6sxupDANIEwM4Occg8+OR6zoR0b4RvL4luxNdyAauf7auAWXaS2/8AefL+8yOMenTivq+igD5Ottf1OH413PlatdzvH4ua1OnwX8xne2YEECDmPyVPJJAPGMivrGiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type I: Mild ramus hypoplasia with body minimally affected. Type II: Small condylar head and ramus, flat infratemporal surface, flat condyle, absent glenoid, and coronoid may be absent. Type III: Ramus thin lamina or absent. No TMJ.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_35_11839=[""].join("\n");
var outline_f11_35_11839=null;
